<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">67932</article-id><article-id pub-id-type="doi">10.7554/eLife.67932</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Wnt signaling enhances macrophage responses to IL-4 and promotes resolution of atherosclerosis</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-228222"><name><surname>Weinstock</surname><given-names>Ada</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3619-3388</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228223"><name><surname>Rahman</surname><given-names>Karishma</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund19"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228224"><name><surname>Yaacov</surname><given-names>Or</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8496-2607</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230315"><name><surname>Nishi</surname><given-names>Hitoo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228225"><name><surname>Menon</surname><given-names>Prashanthi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228226"><name><surname>Nikain</surname><given-names>Cyrus A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228227"><name><surname>Garabedian</surname><given-names>Michela L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228228"><name><surname>Pena</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228229"><name><surname>Akbar</surname><given-names>Naveed</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228252"><name><surname>Sansbury</surname><given-names>Brian E</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228230"><name><surname>Heffron</surname><given-names>Sean P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228231"><name><surname>Liu</surname><given-names>Jianhua</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228232"><name><surname>Marecki</surname><given-names>Gregory</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228233"><name><surname>Fernandez</surname><given-names>Dawn</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund16"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228234"><name><surname>Brown</surname><given-names>Emily J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210942"><name><surname>Ruggles</surname><given-names>Kelly V</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0152-0863</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-65896"><name><surname>Ramsey</surname><given-names>Stephen A</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228235"><name><surname>Giannarelli</surname><given-names>Chiara</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund15"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-109978"><name><surname>Spite</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund17"/><xref ref-type="other" rid="fund18"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-179254"><name><surname>Choudhury</surname><given-names>Robin P</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210940"><name><surname>Loke</surname><given-names>P'ng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6211-3292</contrib-id><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">†</xref></contrib><contrib contrib-type="author" corresp="yes" id="author-28084"><name><surname>Fisher</surname><given-names>Edward A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9802-143X</contrib-id><email>Edward.Fisher@nyulangone.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Medicine, Leon H. Charney Division of Cardiology, Cardiovascular Research Program, New York University Grossman School of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution>Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>NYU Center for the Prevention of Cardiovascular Disease, New York University Grossman School of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Surgery, Mount Sinai School of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Cardiovascular Research Center, Department of Medicine, Icahn School of Medicine at Mount Sinai</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Division of Translational Medicine, Department of Medicine, New York University Langone Health, Institute for Systems Genetics, New York University Grossman School of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Department of Biomedical Sciences, School of Electrical Engineering and Computer Science, Oregon State University</institution><addr-line><named-content content-type="city">Corvallis</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution>Department of Microbiology (Parasitology), New York University School of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution>Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff13"><label>13</label><institution>Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff14"><label>14</label><institution>Departments of Cell Biology and Microbiology, New York University Grossman School of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing Editor</role><aff><institution>James J. Peters Veterans Affairs Medical Center</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p> Laboratoryof Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>15</day><month>03</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e67932</elocation-id><history><date date-type="received" iso-8601-date="2021-02-27"><day>27</day><month>02</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-03-01"><day>01</day><month>03</month><year>2021</year></date></history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-67932-v3.pdf"/><abstract><p>Atherosclerosis is a disease of chronic inflammation. We investigated the roles of the cytokines IL-4 and IL-13, the classical activators of STAT6, in the resolution of atherosclerosis inflammation. Using <italic>Il4<sup>-/-</sup>Il13<sup>-/-</sup></italic> mice, resolution was impaired, and in control mice, in both progressing and resolving plaques, levels of IL-4 were stably low and IL-13 was undetectable. This suggested that IL-4 is required for atherosclerosis resolution, but collaborates with other factors. We had observed increased Wnt signaling in macrophages in resolving plaques, and human genetic data from others showed that a loss-of-function Wnt mutation was associated with premature atherosclerosis. We now find an inverse association between activation of Wnt signaling and disease severity in mice and humans. Wnt enhanced the expression of inflammation resolving factors after treatment with plaque-relevant low concentrations of IL-4. Mechanistically, activation of the Wnt pathway following lipid lowering potentiates IL-4 responsiveness in macrophages via a PGE<sub>2</sub>/STAT3 axis.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>atherosclerosis resolution</kwd><kwd>Wnt</kwd><kwd>IL4</kwd><kwd>pge2</kwd><kwd>STAT3</kwd><kwd>macrophages</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>K23HL135398</award-id><principal-award-recipient><name><surname>Heffron</surname><given-names>Sean P</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>HL136044</award-id><principal-award-recipient><name><surname>Sansbury</surname><given-names>Brian E</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006492</institution-id><institution>Division of Intramural Research, National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>AI130945</award-id><principal-award-recipient><name><surname>Loke</surname><given-names>P'ng</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006492</institution-id><institution>Division of Intramural Research, National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>AI133977</award-id><principal-award-recipient><name><surname>Loke</surname><given-names>P'ng</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>HL084312</award-id><principal-award-recipient><name><surname>Loke</surname><given-names>P'ng</given-names></name><name><surname>Fisher</surname><given-names>Edward A</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>U.S. Department of Defense</institution></institution-wrap></funding-source><award-id>W81XWH-16-1-0256</award-id><principal-award-recipient><name><surname>Loke</surname><given-names>P'ng</given-names></name><name><surname>Fisher</surname><given-names>Edward A</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>18POST34080390</award-id><principal-award-recipient><name><surname>Weinstock</surname><given-names>Ada</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006492</institution-id><institution>Division of Intramural Research, National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>T32AI100853</award-id><principal-award-recipient><name><surname>Rahman</surname><given-names>Karishma</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>F30HL131183</award-id><principal-award-recipient><name><surname>Rahman</surname><given-names>Karishma</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>K99HL151963</award-id><principal-award-recipient><name><surname>Weinstock</surname><given-names>Ada</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>20SFRN35210252</award-id><principal-award-recipient><name><surname>Giannarelli</surname><given-names>Chiara</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R03HL13528</award-id><principal-award-recipient><name><surname>Giannarelli</surname><given-names>Chiara</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>K23HL111339</award-id><principal-award-recipient><name><surname>Giannarelli</surname><given-names>Chiara</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R21TR001739</award-id><principal-award-recipient><name><surname>Giannarelli</surname><given-names>Chiara</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>UH2/3TR002067</award-id><principal-award-recipient><name><surname>Giannarelli</surname><given-names>Chiara</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>5T23HL007824</award-id><principal-award-recipient><name><surname>Fernandez</surname><given-names>Dawn</given-names></name></principal-award-recipient></award-group><award-group id="fund17"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>HL106173</award-id><principal-award-recipient><name><surname>Spite</surname><given-names>Matthew</given-names></name></principal-award-recipient></award-group><award-group id="fund18"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>GM095467</award-id><principal-award-recipient><name><surname>Spite</surname><given-names>Matthew</given-names></name></principal-award-recipient></award-group><award-group id="fund19"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>NIH</institution></institution-wrap></funding-source><award-id>T32GM007308</award-id><principal-award-recipient><name><surname>Rahman</surname><given-names>Karishma</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Wnt signaling is revealed to be a regulator of macrophage inflammation-resolving state in atherosclerosis through a PGE2-mediated pathway.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The past several decades have seen large reductions in fatal and non-fatal complications arising from atherosclerosis, but the most recent data show that these are on the rise again (<xref ref-type="bibr" rid="bib68">Xu et al., 2016</xref>). According to the World Health Organization, atherosclerotic cardiovascular disease is still the leading cause of morbidity and mortality worldwide (<xref ref-type="bibr" rid="bib67">WHO, 2017</xref>). Current therapies aim at inhibiting further progression of the disease, most commonly by lowering low-density lipoprotein (LDL) cholesterol levels. When most patients present for cardiovascular risk reduction, they already have advanced, complex and potentially dangerous plaques. Indeed, several clinical trials examining the effectiveness of available therapies concluded that the majority of treated patients will still undergo major coronary events (<xref ref-type="bibr" rid="bib33">Libby, 2005</xref>). Hence, the resolution of atherosclerosis remains a vital clinical goal.</p><p>We and our collaborators have previously demonstrated a range of resolution of atherosclerosis in several mouse models (<xref ref-type="bibr" rid="bib51">Rahman et al., 2017</xref>; <xref ref-type="bibr" rid="bib48">Peled et al., 2017</xref>; <xref ref-type="bibr" rid="bib18">Feig et al., 2011a</xref>; <xref ref-type="bibr" rid="bib11">Chereshnev et al., 2003</xref>; <xref ref-type="bibr" rid="bib52">Rahman and Fisher, 2018</xref>; <xref ref-type="bibr" rid="bib49">Potteaux et al., 2011</xref>; <xref ref-type="bibr" rid="bib5">Basu et al., 2018</xref>). We have utilized these models to identify and investigate the involved pathways. Collectively, our studies demonstrated that resolution entails a net decrease in plaque macrophage content, with the remaining macrophages showing a pro-resolving phenotype (<xref ref-type="bibr" rid="bib52">Rahman and Fisher, 2018</xref>). For example, during disease progression, plaque macrophages are predominantly inflammatory, expressing factors such as C-C motif chemokine ligand 2 (CCL2) 1, tumor necrosis factor (TNF) ɑ, and vascular cell adhesion molecule (VCAM) 1 (<xref ref-type="bibr" rid="bib47">Parathath et al., 2011</xref>; <xref ref-type="bibr" rid="bib14">Cybulsky et al., 2001</xref>; <xref ref-type="bibr" rid="bib13">Combadière et al., 2008</xref>; <xref ref-type="bibr" rid="bib9">Boyle et al., 2003</xref>; <xref ref-type="bibr" rid="bib19">Feig et al., 2011b</xref>). Conversely, during resolution there is an accumulation of inflammation-resolving, tissue remodeling macrophages, which express arginase (ARG) 1 and mannose receptor (MRC) 1, and the concomitant loss of macrophages with the inflammatory subtype (<xref ref-type="bibr" rid="bib19">Feig et al., 2011b</xref>; <xref ref-type="bibr" rid="bib27">Hewing et al., 2013</xref>).</p><p>ARG1 has been previously considered to be a beneficial factor in atherosclerosis. A potential basis for this is that increased ARG1 activity would limit substrate to iNOS for conversion to damaging reactive nitrogen species (<xref ref-type="bibr" rid="bib45">Munder, 2009</xref>). More recently, ARG1 was shown to aid the licensing of macrophages to clear multiple apoptotic cells, which would be expected to be important in atherosclerosis resolution (<xref ref-type="bibr" rid="bib70">Yurdagul et al., 2020</xref>). <italic>Arg1</italic> expression is mainly regulated through the canonical transcription factor for type 2 immune responses, signal transducer and activator of transcription (STAT) 6 (<xref ref-type="bibr" rid="bib64">Van Dyken and Locksley, 2013</xref>; <xref ref-type="bibr" rid="bib56">Rutschman et al., 2001</xref>). Importantly, we recently showed that STAT6 is necessary for resolution of murine atherosclerosis in a process that also requires monocytes to be recruited to resolving plaques (<xref ref-type="bibr" rid="bib51">Rahman et al., 2017</xref>).</p><p>In the present study, we aimed at determining the signals upstream of STAT6 that induce resolution of atherosclerosis and hypothesized that the classical activators of STAT6, IL-4, and/or IL-13 are involved. Our data show that IL-4 is indeed necessary, but that there are also additional factors operating in concert with it, one of which is Wnt.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Deficiency in <italic>Il4/13</italic> impairs the resolution of atherosclerosis</title><p>To begin to understand the factors upstream of STAT6 needed for atherosclerosis resolution, we examined the requirements for the canonical activators of STAT6, namely IL-4 and IL-13. Mice deficient in both <italic>Il4</italic> and <italic>Il13</italic> (<italic>Il4<sup>-/-</sup>Il13<sup>-/-</sup></italic>) were injected with a liver-specific AAV expressing <italic>Pcsk9</italic> to result in LDLr deficiency and fed Western diet (WD) to promote hypercholesterolemia in order to develop advanced atherosclerotic lesions by 20 weeks (<xref ref-type="bibr" rid="bib6">Bjørklund et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Roche-Molina et al., 2015</xref>; <xref ref-type="bibr" rid="bib48">Peled et al., 2017</xref>). At this time, a baseline (BL) group was harvested to examine the size and composition of the established plaques. To decrease plasma cholesterol thereafter and induce resolution of atherosclerosis (Res), mice were injected with an anti-sense oligonucleotide (ASO) to apolipoproteinB (ApoB) and switched to chow diet for 3 weeks, as described (<xref ref-type="bibr" rid="bib36">Lin et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Sharma et al., 2020</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Global IL-4/13 deficiency impairs atherosclerosis resolution.</title><p>(<bold>A</bold>) Experimental design. (<bold>B</bold>) Plasma cholesterol. Aortic root morphometric analysis for areas of (<bold>C</bold>) plaque, (<bold>D</bold>) CD68, (<bold>E</bold>) % of plaque positive for CD68, (<bold>F</bold>) representative images (red, CD68; scale bar, 200 µm), and (<bold>G</bold>) necrotic core. ****p&lt;0.0001, as determined via two-tailed Student's <italic>t</italic>-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig1-v3.tif"/></fig><p>Treatment with the <italic>Pcsk9</italic> AAV and WD caused a significant increase in total plasma cholesterol (~500 mg/dL), whereas subsequent ApoB ASO injections decreased plasma cholesterol to normal levels (~60 mg/dL, <xref ref-type="fig" rid="fig1">Figure 1B</xref>). We previously showed, in an identical experimental design, that ApoB ASO administration to <italic>Pcsk9</italic> AAV and WD-treated WT mice for 3 weeks resulted in decreased plaque size and macrophage (CD68+ cells) content in aortic roots (<xref ref-type="bibr" rid="bib59">Sharma et al., 2020</xref>). In the present study, following cholesterol lowering, there were no significant changes in aortic root plaque size (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), macrophage content (<xref ref-type="fig" rid="fig1">Figure 1D–F</xref>), or necrotic core area (<xref ref-type="fig" rid="fig1">Figure 1G</xref>) in mice deficient in IL-4 and IL-13. Collectively, these data indicate that IL-4/13 are needed for atherosclerosis resolution.</p></sec><sec id="s2-2"><title>IL-4/13 produced by cells newly recruited to plaques upon cholesterol lowering are dispensable for resolution of atherosclerosis</title><p>We previously reported that atherosclerosis resolution requires recruitment of new <italic>Stat6</italic>-expressing monocytes to plaques (<xref ref-type="bibr" rid="bib51">Rahman et al., 2017</xref>). Because we demonstrated that IL-4/13 are important for atherosclerosis resolution (<xref ref-type="fig" rid="fig1">Figure 1</xref>), we next examined whether the source of the IL-4/13 is from cells newly recruited in the resolution phase or from cells in the plaques prior to the induction of lipid lowering.</p><p>Thus, we performed aortic arch transplant studies (as described previously <xref ref-type="bibr" rid="bib51">Rahman et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Chereshnev et al., 2003</xref>), in which aortic arches from hyperlipidemic <italic>Ldlr</italic><sup>-/-</sup> donors fed WD for 20 weeks (BL group) were transplanted into normolipidemic WT or <italic>Il4<sup>-/-</sup>Il13<sup>-/-</sup></italic> mice. Four weeks post transplant, the grafted aortic segments were evaluated for plaque burden and macrophage content (see Experimental design; <xref ref-type="fig" rid="fig2">Figure 2A</xref>). As expected, the arch donors (and BL group) had elevated total cholesterol levels (978 ± 141 mg/dL), whereas the transplant recipients were normocholesterolemic (79 ± 22 mg/dL and 73 ± 10 mg/dL for WT and <italic>Il4<sup>-/-</sup>Il13<sup>-/</sup></italic><sup>-</sup> mice, respectively; <xref ref-type="fig" rid="fig2">Figure 2B</xref>). Although plaque size did not change significantly between the BL and transplant recipients (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), there was a significant and comparable reduction (~60%) in plaque macrophages in both the WT and <italic>Il4<sup>-/-</sup>Il13<sup>-/-</sup></italic> recipient groups (<xref ref-type="fig" rid="fig2">Figure 2D, E</xref>). The necrotic core area significantly diminished as well in both recipient groups (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Thus, resolution of atherosclerosis was similar in WT and <italic>Il4<sup>-/-</sup>Il13<sup>-/-</sup></italic> recipients (<xref ref-type="fig" rid="fig2">Figure 2D–G</xref>), indicating that IL-4/13 production by cells newly recruited is not essential for resolution of atherosclerosis. These results were confirmed in an additional aortic transplant experiment, in which plaque-bearing aortic arches from <italic>Apoe</italic><sup>-/-</sup> donors fed WD for 16 weeks were grafted into either WT or <italic>Il4</italic><sup>-/-</sup> recipients for 2 weeks (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>), resulting in plaque size and macrophage content changes consistent with those in <italic>Il4<sup>-/-</sup>Il13<sup>-/-</sup></italic> transplant recipients (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B–G</xref>). Notably, there was a marked decrease in macrophage content of both WT and <italic>Il4</italic><sup>-/-</sup> arch recipients (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D–E, G</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Production of IL-4/13 by newly recruited cells is not required for resolution of atherosclerosis.</title><p>(<bold>A</bold>) Experimental design. (<bold>B</bold>) Plasma cholesterol. (<bold>C–G</bold>) Morphometric analysis and representative images of grafted aortic arches for areas of (<bold>C</bold>) plaque, (<bold>D</bold>) CD68, (<bold>E</bold>) % of plaque positive for CD68, and (<bold>F</bold>) necrotic core. Red, CD68; scale bar, 100 µm. ****p&lt;0.0001 and *p&lt;0.05 compared with the baseline group as determined via one-way ANOVA and Dunnett’s multiple comparison test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Production of IL-4 by newly recruited cells is not required for resolution of atherosclerosis.</title><p>(<bold>A</bold>) Experimental design. (<bold>B</bold>) Plasma cholesterol. (<bold>C–F</bold>) Morphometric analysis, and (<bold>G</bold>) representative images of grafted aortic arches for areas of (<bold>C</bold>) plaque, (<bold>D</bold>) CD68, (<bold>E</bold>) % of plaque positive for CD68, and (<bold>F</bold>) necrotic core. Red, CD68; scale bar, 100 µm. ****p&lt;0.0001 and ***p&lt;0.001 compared with the baseline group as determined via one-way ANOVA and Dunnett’s multiple comparison test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig2-figsupp1-v3.tif"/></fig></fig-group><p>Our data thus far indicate that IL-4/13 are needed for atherosclerosis resolution, and the source of these cytokines is not from cells that are newly recruited in the resolution phase, but from cells accumulating during the disease progression phase.</p></sec><sec id="s2-3"><title>IL-4/13 content in plaques is unchanged between atherosclerosis progression and resolution</title><p>We next evaluated whether IL-4/13 content is increased during atherosclerosis resolution. To measure cytokine abundances in plaques, <italic>Ldlr</italic><sup>-/-</sup> mice fed WD for 20 weeks (BL) and treated with ApoB ASO for an additional 3 weeks (Res) were examined. Upon harvest, plaques from aortic arches and brachiocephalic arteries were carefully excised and evaluated for CCL2, IL-4, and IL-13. CCL2 was used as a control since we previously showed that its levels are decreased in resolving plaques (<xref ref-type="bibr" rid="bib51">Rahman et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Feig et al., 2011b</xref>). Consistent with our previous reports (e.g., <xref ref-type="bibr" rid="bib55">Rong et al., 2001</xref>), CCL2 abundance in plaques showed a marked decrease from progression to resolution (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>IL-4/13 levels do not change during resolution of atherosclerosis.</title><p>(<bold>A</bold>) Quantification of CCL2, IL-4, and IL-13 protein levels in aortic arch plaques of <italic>Ldlr<sup>-/-</sup></italic> BL mice or further treated for lipid lowering for 3 weeks (Res). (<bold>B</bold>) Experimental design. (<bold>C</bold>) CD68-positive area in aortic roots. (<bold>D</bold>) Gating scheme of aortic arches single-cell suspensions and (<bold>E</bold>) quantification of IL-4 (eGFP+) producing cells in aortic arches. **p&lt;0.01 and *p&lt;0.05 determined by an unpaired <italic>t</italic>-test (two-tailed).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title><italic>Il13</italic> expression in plaques during disease progression and resolution on a single cell level.</title><p><italic>Il13</italic> gene expression in plaque immune cells (from <xref ref-type="bibr" rid="bib59">Sharma et al., 2020</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig3-figsupp1-v3.tif"/></fig></fig-group><p>In contrast to CCL2, IL-4 levels did not significantly change between progression (111 pg/mL) and resolution (123 pg/mL; <xref ref-type="fig" rid="fig3">Figure 3A</xref>) and were strikingly lower (over two orders of magnitude) than those commonly used in cell culture experiments (10–20 ng/mL) (<xref ref-type="bibr" rid="bib44">Minutti et al., 2017</xref>; <xref ref-type="bibr" rid="bib8">Bosurgi et al., 2017</xref>; <xref ref-type="bibr" rid="bib57">Sanin et al., 2018</xref>). Interestingly, IL-13 was undetectable (&lt;3 pg/mL) in both progressing and resolving plaques. To confirm that plaque IL-13 levels are negligible, we examined its expression in a recently published dataset of plaque immune cells pre- and post-atherosclerosis resolution (<xref ref-type="bibr" rid="bib59">Sharma et al., 2020</xref>). In accordance with the undetectable protein levels, only one cell in the entire dataset showed <italic>Il13</italic> expression (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Hence, we focused on IL-4 in subsequent experiments.</p><p>Because IL-4 production is needed in cells that accumulate during atherosclerosis progression, but not in cells newly recruited during resolution (<xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig2">2</xref>), we next examined the abundance of IL-4-producing cells in plaques. IL-4-reporter mice were injected with <italic>Pcsk9-</italic>AAV and fed WD for 16 weeks to promote atherosclerosis formation. BL mice were harvested, and the disease resolution group was induced with ApoB ASO treatment and chow diet (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). We confirmed that ApoB ASO treatment led to reduction in plaque macrophages and promoted resolution of atherosclerosis (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Aortic arches were digested and analyzed using flow cytometry (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Results showed no significant difference in the proportion of IL-4-producing leukocytes (CD45+ cells) when comparing mice from the BL (3.3%) and resolution (2.7%) groups (<xref ref-type="fig" rid="fig3">Figure 3E</xref>).</p><p>Our data suggest that small amounts of IL-4-producing cells accumulate in progressing plaques and do not increase further during the resolution phase. In the reparative environment, the IL-4 that accumulated is apparently sufficient to activate STAT6, which in turn polarizes plaque macrophages to pro-resolving cells.</p></sec><sec id="s2-4"><title>Macrophage Wnt signaling is associated with disease resolution and decreased atherosclerosis severity in mice and humans</title><p>Because IL-4 levels do not change in resolving plaques, we postulated that this environment contains other factors that license IL-4 activation of STAT6.</p><p>To explore this, we reviewed our transcriptome data from macrophages taken by laser-capture microdissection from progressing and resolving plaques (<xref ref-type="bibr" rid="bib53">Ramsey et al., 2014</xref>). These data (from two independent mouse models (<xref ref-type="bibr" rid="bib18">Feig et al., 2011a</xref>) suggested activation of the Wnt pathway (<xref ref-type="bibr" rid="bib53">Ramsey et al., 2014</xref>). This was of particular interest since a mutation causing downregulation of this pathway led to early coronary artery disease in humans (<xref ref-type="bibr" rid="bib42">Mani et al., 2007</xref>). Moreover, activation of Wnt signaling in macrophages was recently shown to inhibit atherosclerosis progression (<xref ref-type="bibr" rid="bib66">Wang et al., 2018</xref>).</p><p>To confirm this activation in resolving plaques, single-cell RNA-sequencing (scRNA-seq) data from progressing and resolving plaque macrophages that we recently published (<xref ref-type="bibr" rid="bib36">Lin et al., 2019</xref>) were analyzed for the expression of Wnt-related genes (GO term GO0060070 ‘Wnt signaling Pathway’). The expression of these genes was summed per cell, aggregated by Louvain clusters and plotted (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). This analysis showed expression of Wnt-related genes in all the macrophage clusters (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Notably, comparison between progressing and resolving plaque macrophages demonstrated that in disease resolution there is an overall increase in the expression of Wnt-related genes across most clusters (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The relative expression levels of each Wnt-related gene from resolving versus progressing plaque macrophages are presented in <xref ref-type="fig" rid="fig4">Figure 4C</xref>. Among the Wnt regulated genes, <italic>Cttnb1</italic>, the gene encoding for β-catenin, the downstream canonical effector of Wnt, was the most upregulated across macrophage clusters (<xref ref-type="fig" rid="fig4">Figure 4C</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Atherosclerosis severity is associated with decreased responsiveness of plaque macrophages to Wnt signaling in mice and humans.</title><p>(<bold>A–C</bold>) Cumulative expression of genes associated with the GO term GO:0016055 of data from <xref ref-type="bibr" rid="bib36">Lin et al., 2019</xref> represented in (<bold>A</bold>) Louvain clusters for both progression and resolution groups and (<bold>B</bold>) divided by treatment. (<bold>C</bold>) Individual GO:0016055 gene expression per cluster, comparing treatment groups. Red, higher expression in resolution; blue, higher expression in progression. (<bold>D</bold>) Human plaque macrophages obtained from endarterectomies (from <xref ref-type="bibr" rid="bib22">Fernandez et al., 2019</xref>) were examined for their expression of the top 10 most upregulated genes from GO:0016055 in mouse resolving plaque macrophages (from <xref ref-type="bibr" rid="bib36">Lin et al., 2019</xref>). Relative expression of symptomatic (Sym) versus asymptomatic (Asym) is presented. Permutation tests of Fernandez et al. expressed genes was performed to calculate the probability of 7 or more genes out of 10 to have lower expression in the Sym group, p=0.008. (<bold>E</bold>) Expression of seven Wnt marker genes (<italic>Axin2, Ddx3x, Wls, Senp2, Ctnnb1, Csnk1a1,</italic> and <italic>Amfr</italic>) was measured in peripheral blood mononuclear cells (PBMCs) from statin-naïve patients at presentation of acute coronary syndrome and 3 months intensive atorvastatin treatment follow-up (<xref ref-type="bibr" rid="bib1">Alkhalil et al., 2018</xref>). (<bold>F</bold>) Change in the expression of the Wnt hallmark gene, <italic>Axin2,</italic> in PBMCs obtained from patients was examined in relation to change in plaque volume from presentation to follow-up (<xref ref-type="bibr" rid="bib1">Alkhalil et al., 2018</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig4-v3.tif"/></fig><p>To extend our analysis of Wnt signaling to human plaque macrophages, we analyzed a recently published dataset characterizing the transcriptome of human endarterectomy leukocytes (<xref ref-type="bibr" rid="bib22">Fernandez et al., 2019</xref>). First, Wnt-responsive gene expression data from mouse plaque macrophages (<xref ref-type="fig" rid="fig4">Figure 4C</xref>) were averaged across all clusters. The 10 highest differentially expressed genes in resolving plaques were identified and their expression examined in carotid plaque macrophages from symptomatic (Sym) versus asymptomatic (Asym) patients (<xref ref-type="bibr" rid="bib22">Fernandez et al., 2019</xref>; <xref ref-type="fig" rid="fig4">Figure 4D</xref>). Results show that of the 10 genes 7 had lower expression levels in Sym patients’ plaque macrophages compared to Asym patients (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). A permutation test resulted in a p-value=0.008, thereby supporting a <italic>bona fide</italic> inverse relationship between Wnt signaling and disease severity across species, consistent with the genetic loss-of-function association with premature CAD (coronary artery disease; <xref ref-type="bibr" rid="bib42">Mani et al., 2007</xref>).</p><p>To independently support the clinical relevance of the inverse relationship between Wnt signaling and disease severity, we next examined whether the Wnt pathway is associated with atherosclerosis resolution in humans. A recently described cohort of statin-naïve patients that were treated with high-dose atorvastatin following presentation with an acute coronary syndrome (<xref ref-type="bibr" rid="bib1">Alkhalil et al., 2018</xref>) was used. Using advanced imaging techniques, the authors evaluated carotid artery plaque volume at presentation and 3 months later. We investigated the expression of seven Wnt-associated genes (<italic>Axin2, Ddx3x, Wls, Senp2, Ctnnb1, Csnk1a1,</italic> and <italic>Amfr</italic>) in peripheral blood mononuclear cells (PBMCs) obtained at presentation and follow-up. The fold-change of each gene expression at the follow-up compared to presentation was calculated per patient and summed to create a ‘Wnt score’. These scores at the 3-month follow-up were significantly increased relative to disease presentation, indicated by the increased Wnt score (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Notably, the expression of <italic>Axin2</italic>, the hallmark Wnt target gene (<xref ref-type="bibr" rid="bib29">Jho et al., 2002</xref>; <xref ref-type="bibr" rid="bib40">Lustig et al., 2002</xref>), significantly correlated with a decrease in plaque volume (R<sup>2</sup> = 0.408, p=0.002; <xref ref-type="fig" rid="fig4">Figure 4F</xref>). These data provide further support that atherosclerosis resolution is associated with upregulation of the Wnt pathway not only in mice, but also in humans.</p></sec><sec id="s2-5"><title>The Wnt signaling pathway collaborates with IL-4 to enhance expression of macrophage pro-resolving genes in vitro</title><p>Because Wnt signaling is upregulated in resolving plaque macrophages and IL-4 levels were similar in progressing and resolving plaques, we examined whether this pathway augments the effects of IL-4. Wnt3a is a wnt pathway activator and is most commonly used for studies in vitro. Thus, we treated bone marrow-derived macrophages (BMDMs) with recombinant Wnt3a protein and IL-4 (at its plaque concentration). First, we confirmed that treatment with Wnt3a activated the Wnt pathway, indicated by the upregulation of <italic>Axin2</italic> (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>) and the accumulation of the transcription co-activator β-catenin (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Examination of genes associated with pro-resolution (e.g., <italic>Arg1</italic>, <italic>Ccl17,</italic> and <italic>Socs1</italic>) revealed that Wnt3a treatment did not alter their expression. However, when cells were co-treated with Wnt3a and IL-4, these transcripts showed increased expression relative to IL-4 alone (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Wnt3a enhances macrophage IL-4-induced gene expression in vitro.</title><p>Bone marrow-derived macrophages from WT (<bold>A–C</bold>), <italic>Il4<sup>-/-</sup>Il13<sup>-/-</sup></italic> (<bold>D–F</bold>), or <italic>Stat6</italic><sup>-/-</sup> (<bold>G–I</bold>) mice were treated with Wnt3a, IL-4, or their combination for 16 hr and expression of (<bold>A</bold>/<bold>D</bold>/<bold>G</bold>) <italic>Arg1</italic>, (<bold>B</bold>/<bold>E</bold>/<bold>H</bold>) <italic>Ccl17,</italic> and (<bold>C</bold>/<bold>F</bold>/<bold>I</bold>) <italic>Socs1</italic> was determined using qPCR. p-Values were determined via (<bold>A–C</bold>) one-way ANOVA or (<bold>D–I</bold>) two-way ANOVA compared with IL-4 treatment and Dunnett’s multiple comparison test (with repeated measurements). *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Macrophage responsiveness to Wnt stimulation in vitro.</title><p>(<bold>A</bold>) WT bone marrow-derived macrophages were treated with Wnt3a and IL4 (as in <xref ref-type="fig" rid="fig5">Figure 5</xref>) and expression of Axin2 determined with qPCR. *p&lt;0.05 compared with the untreated group as determined via 1-way ANOVA and Dunnett’s multiple comparison test (with repeated measurements). (<bold>B</bold>) Representative western blot image for β-catenin and GAPDH of bone marrow-derived macrophages treated with Wnt3a for 1 hour (one out of 3 independent experiments).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig5-figsupp1-v3.tif"/></fig></fig-group><p>To examine whether the enhanced expression of these pro-resolving genes is due to Wnt3a-induced production of IL-4/13, we repeated the in vitro experiments with <italic>Il4<sup>-/-</sup>Il13<sup>-/-</sup></italic> BMDMs. The data show that the expression of the pro-resolving genes was enhanced in cells co-treated with Wnt3a and IL-4 (<xref ref-type="fig" rid="fig5">Figure 5D–F</xref>), indicating that the increased gene expression cannot be explained by induced production of IL-4/13. Since the signal transducer of IL-4 is STAT6 (as noted above, previously shown to be required for plaque resolution <xref ref-type="bibr" rid="bib51">Rahman et al., 2017</xref>), we studied its involvement in the enhanced pro-resolving gene expression by using BMDMs from <italic>Stat6</italic><sup>-/-</sup> mice. As shown in <xref ref-type="fig" rid="fig5">Figure 5G–I</xref>, <italic>Stat6</italic> deficiency completely abrogated the expression of <italic>Arg1</italic>, <italic>Ccl17,</italic> and <italic>Socs1</italic> and the enhancement observed in cells co-treated with Wnt3a and IL-4. In sum, the data suggest that Wnt signaling cooperates with IL-4/STAT6 signaling to augment macrophage pro-resolving gene expression.</p></sec><sec id="s2-6"><title>Wnt signaling is required for the resolution of atherosclerosis</title><p>Our in vitro and in vivo data suggest a role for the Wnt signaling pathway in resolving atherosclerosis. To strengthen this suggestion, we performed an atherosclerosis resolution study. Reversa mice (<xref ref-type="bibr" rid="bib18">Feig et al., 2011a</xref>) were fed WD for 16 weeks to establish advanced atherosclerotic plaques (baseline group; BL). LDL-C levels were then lowered and mice treated with an established Wnt inhibitor, LGK974 (<xref ref-type="bibr" rid="bib37">Liu et al., 2013</xref>), or vehicle, for an additional 3 weeks (<xref ref-type="fig" rid="fig6">Figure 6A</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Wnt inhibition impairs atherosclerosis resolution and reparative macrophage polarization.</title><p>(<bold>A</bold>) Experimental design. (<bold>B</bold>) Plasma cholesterol. Aortic root morphometric analysis for areas of (<bold>C</bold>) plaque, (<bold>D</bold>) CD68, and (<bold>E</bold>) %of plaque positive for CD68. (<bold>F</bold>) Representative images and (<sc><bold>G</bold></sc>) quantification of aortic roots stained for (from left to right) CD68, collagen (with picrosirius red, imaged in bright field and under polarized light), vascular cell adhesion molecule 1, C-C motif chemokine ligand 2, mannose receptor 1MRC1, and arginase 1. Scale bar, 200 µm for CD68 and collagen, 50 µm for others. The dashed line demarcates plaque, and L stands for lumen. ****p&lt;0.0001, ***p&lt;0.001, **p&lt;0.01, and *p&lt;0.05 determined via one-way ANOVA comparing each group to the other groups, with Dunnett’s multiple comparison test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig6-v3.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Effects of Wnt inhibition on general physiological parameters.</title><p>(<bold>A</bold>) Body weight and (<bold>C–E</bold>) hematological parameters on harvest day (experimental design in <xref ref-type="fig" rid="fig6">Figure 6A</xref>). p-values were determined via 1-way ANOVA comparing each group to the other 2 groups, with Dunnett’s multiple comparison test. (<bold>F</bold>) Flow-cytometry analysis of circulating monocyte subsets. (<bold>G</bold>) Quantification of aortic root lesions stained for active, non-phosphorylated β-catenin. (<bold>H</bold>) Expression of <italic>Lef1</italic> and <italic>Axin2</italic> (normalized to <italic>Hprt</italic>) in LCM excised macrophages determined by qPCR. (<bold>G-H</bold>) p-values were determined by an unpaired t test (2-tailed), ****p&lt;0.0001, ***p&lt;0.001and *p&lt;0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig6-figsupp1-v3.tif"/></fig></fig-group><p>BL mice were hypercholesterolemic (~810 mg/dL), and mice from both lipid-lowering groups were normocholesterolemic (~140 mg/dL; <xref ref-type="fig" rid="fig6">Figure 6B</xref>). Mice treated with LGK974 had similar body weights (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>), lipid profiles (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), hematological parameters (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B–E</xref>), and frequencies of Ly6C<sup>hi</sup> and Ly6C<sup>lo</sup> circulating monocytes (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>) compared to the control (Ctrl) group. To confirm that Wnt inhibition was successful in the LGK974-treated mice, plaques were stained for the active form of β-catenin (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G</xref>), which showed significantly less active β-catenin. To verify that LGK974 treatment inhibited Wnt signaling in plaque macrophages, we excised them using laser capture microdissection (LCM) and examined the expression of Wnt-responsive genes. The data show decreased expression of <italic>Lef1</italic> and <italic>Axin2</italic> from LGK974 compared to vehicle-treated mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1H</xref>).</p><p>Plaque area and macrophage content were significantly decreased in the control group compared to BL (<xref ref-type="fig" rid="fig6">Figure 6C–F</xref>). However, mice that received the Wnt inhibitor did not have a significant decrease in plaque or macrophage area (<xref ref-type="fig" rid="fig6">Figure 6C–F</xref>), despite equally low cholesterol levels (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Furthermore, we previously reported that resolving plaques are enriched with collagen, presumably because the content of matrix metalloprotease-producing macrophages decline (<xref ref-type="bibr" rid="bib48">Peled et al., 2017</xref>). We again observed this increase in plaque collagen in the control resolution group, but it was not detected in the Wnt inhibitor group (<xref ref-type="fig" rid="fig6">Figure 6F, G</xref>). As noted above, atherosclerosis resolution is characterized by the change in the inflammatory state of plaque macrophages from pro-inflammatory to pro-resolving (<xref ref-type="bibr" rid="bib51">Rahman et al., 2017</xref>; <xref ref-type="bibr" rid="bib53">Ramsey et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Feig et al., 2012</xref>). Consistent with this, plaque immunostaining showed that in control resolution there was downregulation of the pro-inflammatory markers CCL2 and VCAM1, which were not attenuated in the LGK974 group. Additionally, compared to BL mice, in the control group there were increases in pro-resolving markers ARG1 and MRC1, which were not seen in the LGK974 group (<xref ref-type="fig" rid="fig6">Figure 6F, G</xref>). Overall, these data suggest that Wnt inhibition impairs atherosclerosis resolution and results in decreased accumulation of pro-resolving plaque macrophages.</p></sec><sec id="s2-7"><title>STAT3 is activated by Wnt3a and is required for the augmentation of IL-4</title><p>To investigate the molecular mechanisms underlying the enhanced response of BMDMs to Wnt3a and IL-4, we performed RNA-seq of cells treated for 16 hr with media (untreated) or with media containing Wnt3a, IL-4, or Wnt3a+IL-4. Principal component analysis (PCA) shows that the untreated BMDMs cluster with the IL-4-treated cells (<xref ref-type="fig" rid="fig7">Figure 7A</xref>), indicating a high similarity of transcriptional profiles (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>) before Wnt-mediated augmentation. Wnt3a-treated (−/+ IL-4) cells clustered together were distinct from the control and IL-4-treated cells (<xref ref-type="fig" rid="fig7">Figure 7A</xref>) and exhibited extensive transcriptional changes (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). The data suggested a possible engagement of the JAK-STAT pathway in Wnt3a-treated cells as both Wnt3a and Wnt3a+IL-4-treated cells had the KEGG pathway term ‘JAK-STAT signaling pathway’ in the top seven most significantly enriched pathways (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). Of the members of the JAK-STAT pathway, we focused on STAT3 because of its known anti-inflammatory functions (reviewed in <xref ref-type="bibr" rid="bib28">Hillmer et al., 2016</xref>) and its being implicated in Wnt3a-induced enhancement of IL-4 responses of macrophages (<xref ref-type="bibr" rid="bib21">Feng et al., 2018</xref>). Moreover, the STAT3 activating cytokines IL-6 and IL-10 have been reported to collaborate with IL-4 to enhance <italic>Arg1</italic> expression in macrophages (<xref ref-type="bibr" rid="bib41">Makita et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Mauer et al., 2014</xref>), as we also found (<xref ref-type="fig" rid="fig7">Figure 7B, C</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Wnt3a promotes STAT3 activation, which is required for the enhanced pro-resolving phenotype.</title><p>(<bold>A</bold>) Principal component analysis of RNA-seq data acquired from bone marrow-derived macrophages (BMDMs) treated with Wnt3a, IL-4, or their combination. (<bold>B, C</bold>) <italic>Arg1</italic> expression of BMDMs treated with IL-4 and (<bold>B</bold>) IL-6 or (<bold>C</bold>) IL-10. (<bold>D</bold>) Representative western blot image for phosphorylates (pY) and total STAT3 16 hr following treatment of BMDMs with Wnt3a (one out of three independent experiments). (<bold>E</bold>) BMDMs were treated with Wnt3a for 16 hr, and <italic>Socs3</italic> expression was determined using qPCR. p-Value was determined by a paired <italic>t</italic>-test (two-tailed). (<bold>F</bold>) BMDMs were treated with control or STAT3 siRNA, followed by treatment with Wnt3a, IL-4, or their combination and <italic>Arg1</italic> expression determined using qPCR. p-Values were determined via (<bold>B, C</bold>) one-way or (<bold>F</bold>) two-way ANOVA compared with IL-4 treatment. Between siRNA groups, p-values were determined via two-way ANOVA comparing same Wnt3a/IL-4 treatments and Dunnett’s multiple comparison test (with repeated measurements). ***p&lt;0.001, **p&lt;0.01, and *p&lt;0.05. (<bold>G</bold>). Representative images of aortic roots from control (Ctrl) or LGK974-treated mice (as in <xref ref-type="fig" rid="fig6">Figure 6A</xref>) stained for nuclei (blue) and STAT3 (gray). Scale bar, 100 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig7-v3.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>STAT3 involvement in the Wnt3a-mediated enhancement of IL-4 response.</title><p>(<bold>A</bold>) Proportion of differentially expressed genes (using RNA-seq) of bone marrow-derived macrophages (BMDMs) treated with IL-4 (green), Wnt3a (orange), or their combination (purple) compared to untreated cells. (<bold>B</bold>) Top eight GO terms of differentially expressed genes in Wnt3a and Wnt3a+IL-4-treated BMDMs. (<bold>C</bold>) Representative western blot image for phosphorylates (pY) and total STAT3 following treatment of BMDMs with Wnt3a for the indicated times (one out of two independent experiments). (<bold>D</bold>) BMDMs used in <xref ref-type="fig" rid="fig7">Figure 7F</xref> were examined for STAT3 expression using qPCR. (<bold>E</bold>) Representative western blot image for phosphorylates and total STAT3, as well as GAPDH, following treatment of BMDMs with Wnt3a or its conditioned media (CM) for the indicated times (one out of three independent experiments). Wnt CM was produced by treatment of BMDMs with Wnt3a for 16 hr. (<bold>F</bold>) BMDMs were treated with Wnt3a for 16 hr and added IL-4 for 2.5 hr thereafter, or with CM+IL-4 for 2.5 hr. Some CM was treated for 1 hr with a blocking antibody to Wnt3a prior to their exposure (in combination with IL4) to naïve BMDMs for 2.5 hr. <italic>Arg1</italic> expression was determined with qPCR. p-Values were determined via one-way ANOVA, compared with IL-4 treatment, and Dunnett’s multiple comparison test (with repeated measurements). (<bold>G</bold>) BMDMs were treated with IL-4, with or without Wnt3a, and with blocking antibodies for transforming growth factor β, C-X-C motif chemokine receptor 3, glycoprotein 103, IL-10 receptor, and hepatocyte growth factor receptor for 16 hr, and <italic>Arg1</italic> expression was determined using real-time qPCR (n = 2–3 mice per treatment).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig7-figsupp1-v3.tif"/></fig></fig-group><p>We next tested whether STAT3 is activated (as reflected by phosphorylation) by Wnt3a in BMDMs. The data show that STAT3 is not phosphorylated after a short exposure to Wnt3a (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C</xref>); however, after 16 hr of treatment, there was substantial STAT3 phosphorylation (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Furthermore, the STAT3 target gene <italic>Socs3</italic> was upregulated following Wnt3a treatment (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). To directly examine the involvement of STAT3 in the enhanced expression of pro-resolving genes following Wnt3a treatment, we knocked-down (KD) <italic>Stat3</italic> mRNA in BMDMs using siRNA and treated these cells with Wnt3a, IL-4, or Wnt3a+IL-4. The siRNA decreased <italic>Stat3</italic> transcript levels by ~80% (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref>). Results show that <italic>Stat3</italic> KD attenuated <italic>Arg1</italic> expression in response to Wnt3a+IL-4 (<xref ref-type="fig" rid="fig7">Figure 7F</xref>), suggesting that STAT3 is required for the enhancement of IL-4 responses by Wnt3a.</p><p>To explore whether Wnt inhibition affects STAT3 activity in vivo, aortic root sections from control and LGK974-treated mice (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) were stained for STAT3, and its nuclear localization was determined. Images and their analyses show less nuclear STAT3 localization in plaques of mice treated with LGK974 compared to the control group (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). Collectively, these data suggest that Wnt enhances the response to IL-4 via STAT3 activation.</p><p>We next aimed at understanding how Wnt signaling promotes STAT3 activation. Since STAT3 is most commonly activated downstream of cytokine receptors, together with our observation that Wnt3a promotes STAT3 phosphorylation 16 hr post treatment, but not in early time points, we postulated that Wnt3a induces the production and secretion of a factor or factors that accumulate in the conditioned media (CM) and activate STAT3 in an autocrine/paracrine manner. To test this hypothesis, CM were generated from BMDMs treated with Wnt3a for 16 hr. Naive BMDMs were then treated with the CM or Wnt3a itself for 15, 30 and 60 min, and STAT3 phosphorylation was examined. The data show that the CM caused STAT3 phosphorylation after 15 min, while Wnt3a itself failed to do so (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1E</xref>). Furthermore, to examine whether Wnt CM augments pro-resolving gene expression, BMDMs were treated with IL-4 for 2.5 hr either after 16 hr of Wnt3a treatment or in combination with Wnt CM. Similar to our previous results, co-treatment of BMDMs with Wnt3a, as well as Wnt CM, in combination with IL-4 promoted enhanced <italic>Arg1</italic> expression compared with IL-4-only treatment (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1F</xref>). To confirm that the augmentation in <italic>Arg1</italic> expression is not due to residual Wnt3a, CM was treated with a Wnt3a-blocking antibody prior to its exposure to naïve BMDMs. The data show that the CM retained its IL-4 augmentation ability (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1F</xref>), suggesting that Wnt3a stimulated the production and/or secretion of a factor/s other than itself that, in turn, activated STAT3.</p><p>As a first step in the investigation of the Wnt3a-stimulated secreted factor that activates STAT3, we mined our RNA-seq dataset (<xref ref-type="fig" rid="fig7">Figure 7A</xref>) for soluble proteins with known links to STAT3 activation that showed differential expression following Wnt3a treatment. This showed differential expression of transforming growth factor β (TGFβ) and C-X-C motif chemokine receptor 3 (CXCR3) in Wnt3a-treated cells. Next, TGFβ and CXCR3, as well as the main receptors upstream of STAT3 activation (glycoprotein 130 [gp130], IL-10 receptor [IL10R], and hepatocyte growth factor receptor [HGFR]), were inhibited using specific blocking antibodies, concomitant with treatment of the BMDMs with IL-4 alone or a combination of IL-4 and Wnt3a. <italic>Arg1</italic> expression was not attenuated by blocking any of the aforementioned proteins in Wnt3a+IL-4-treated cells (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1G</xref>), indicating that these factors do not play a role in the enhanced pro-resolving gene expression following Wnt3a treatment.</p></sec><sec id="s2-8"><title>Wnt3a induces the production of PGE<sub>2</sub>, which causes the enhanced response to IL-4</title><p>Because we could not find a potential secreted protein to activate STAT3 following Wnt3a treatment, together with experiments showing that boiled Wnt CM retained its ability to augment <italic>Arg1</italic> expression (data not shown), we postulated that the Wnt3a-stimulated secreted factor is a lipid. Thus, targeted liquid chromatography-tandem mass spectrometry (LC-MS)/MS metabololipidomics analysis of Wnt3a CM was performed. We were particularly interested in inflammation-resolving lipid mediators (representative MS/MS fragmentation spectra are shown in <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A, B</xref>). We found that several lipid mediators were upregulated in CM of Wnt3a-treated BMDMs (<xref ref-type="fig" rid="fig8">Figure 8A</xref>), notably at the time when CM enhances the response to IL-4. Specifically, there was a global increase of arachidonic acid metabolites, such as TXB<sub>2</sub>, PGE<sub>2</sub>, PGD<sub>2</sub>, PGF<sub>2a</sub>, peaking 16 hr post-Wnt3a treatment (respective fold changes of 18, 58, 101, and 5, <xref ref-type="fig" rid="fig8">Figure 8A</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Wnt3a promotes PGE<sub>2</sub> production that enhances the response to IL-4.</title><p>(<bold>A</bold>) Bone marrow-derived macrophages (BMDMs) were treated with Wnt3a for the indicated times and conditioned media (CM) analyzed using LC-MS/MS. Relative abundance to untreated cells shown. (<bold>B</bold>) Correlation between genes differentially expressed (adjusted p-value&lt;0.05) in Wnt3a+IL-4 (from Weinstock et al.) or PGE<sub>2</sub>+IL-4 (from Sanin et al.). (<bold>C</bold>) BMDMs were treated with Wnt3a for 16 hr and expression of <italic>Ptges</italic>, <italic>Ptgs2,</italic> and <italic>Hpgd</italic> determined with qPCR. (<bold>D</bold>) Wnt CM was obtained (same experiment as <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1F</xref>). Naïve BMDMs were treated with IL-4 or CM+IL-4 for 2.5 hr. CM was treated with a PGE<sub>2</sub> blocking antibody prior to their exposure (with IL-4) to naïve BMDMs. <italic>Arg1</italic> expression was determined. (<bold>E</bold>) BMDMs were treated with Wnt3a for 16 hr and an additional 2.5 hr with IL-4 or with CM+IL-4 for 2.5 hr. Cells were concomitantly treated with either DMSO (Dimethyl sulfoxide; control), EP2 inhibitor, EP4 inhibitor, or their combination for the duration of treatment with Wnt3a or CM. <italic>Arg1</italic> expression was evaluated. p-Values were determined via (<bold>D</bold>) one-way and (<bold>E</bold>) two-way ANOVA, compared with IL-4 treatment, and Dunnett’s multiple comparison test (with repeated measurements). (<bold>F</bold>) Expression of <italic>Ptges</italic>, <italic>Ptgs2,</italic> and <italic>Hpgd</italic> in aortic root plaque macrophages of control (Ctrl) and LGK974 groups (as in <xref ref-type="fig" rid="fig6">Figure 6A</xref>). (<bold>C, F</bold>) p-Values were determined by an unpaired <italic>t</italic>-test (two-tailed). ***p&lt;0.001, ***p&lt;0.01, and *p&lt;0.05. (<bold>G</bold>) Schematic model of findings.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig8-v3.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Prostanoids measurements and PGE<sub>2</sub> cooperation with IL-4.</title><p>(<bold>A, B</bold>) Representative LC-MS/MS fragmentation spectra used for the identification of (<bold>A</bold>) PGE<sub>2</sub> and (<bold>B</bold>) PGD<sub>2</sub>. (<bold>C</bold>) Bone marrow-derived macrophages were treated with IL-4, PGE<sub>2</sub>, or their combination for 2.5 hr and examined for <italic>Arg1</italic> with qPCR. *p&lt;0.05 was determined via one-way ANOVA, compared with IL-4 treatment, and Dunnett’s multiple comparison test (with repeated measurements).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-fig8-figsupp1-v3.tif"/></fig></fig-group><p>Of the upregulated metabolites, we focused on PGE<sub>2</sub> because of its function as an amplifier of IL-4 responses (<xref ref-type="bibr" rid="bib57">Sanin et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Gao et al., 2016</xref>; <xref ref-type="bibr" rid="bib39">Luan et al., 2015</xref>; <xref ref-type="bibr" rid="bib26">Heffron et al., 2021</xref>; <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1C</xref>) and its role as a STAT3 activator in various cell types (<xref ref-type="bibr" rid="bib30">Jw et al., 2019</xref>; <xref ref-type="bibr" rid="bib12">Chun et al., 2010</xref>; <xref ref-type="bibr" rid="bib65">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Halpern et al., 2019</xref>). For example, Sanin et al. recently examined the relationship between PGE<sub>2</sub> and IL-4 to regulate pro-resolving gene expression and have performed RNA-seq of BMDMs co-treated with IL-4 and PGE<sub>2</sub> (<xref ref-type="bibr" rid="bib57">Sanin et al., 2018</xref>). Thus, we compared those data to our RNA-seq data of BMDMs co-treated with Wnt3a and IL-4. The data show a high degree of correlation in gene expression between BMDMs treated with Wnt3a+IL-4 and PGE<sub>2</sub>+IL-4, with r<sup>2</sup> = 0.481 and p-value&lt;2.34<sup>−75</sup> (<xref ref-type="fig" rid="fig8">Figure 8B</xref>), despite marked differences in the IL-4 concentrations used in these experiments (0.1 and 20 ng/mL, <xref ref-type="bibr" rid="bib57">Sanin et al., 2018</xref>, respectively).</p><p>Because the canonical Wnt pathway was previously shown (e.g., <xref ref-type="bibr" rid="bib3">Araki et al., 2003</xref>; <xref ref-type="bibr" rid="bib46">Nunez et al., 2011</xref>) to regulate <italic>Ptgs2</italic> expression (the enzyme that metabolizes arachidonic acid to PGH<sub>2</sub>, the PGE<sub>2</sub> precursor), we examined its levels following Wnt3a stimulation in BMDMs. The results show increased <italic>Ptgs2</italic> expression upon Wnt3a treatment, as well as upregulation of the next enzyme in the PGE<sub>2</sub> production pathway, <italic>Ptges</italic> (<xref ref-type="fig" rid="fig8">Figure 8C</xref>). In addition to the increase in these enzymes that produce PGE<sub>2</sub>, Wnt3a also decreased the expression of <italic>Hpgd</italic>, which inactivates PGE<sub>2</sub> and serves as a negative regulator of its levels (<xref ref-type="fig" rid="fig8">Figure 8C</xref>).</p><p>To directly assess whether PGE<sub>2</sub> is the secreted factor in Wnt3a CM that cooperates with IL-4, we employed two strategies. First, Wnt CM was treated with a PGE<sub>2</sub>-blocking antibody and then added to naive BMDMs together with IL-4 for 2.5 hr. While blocking of Wnt3a itself in Wnt CM did not alter the augmented <italic>Arg1</italic> expression (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1F</xref>), PGE<sub>2</sub> blockade completely abrogated the enhancement in gene expression (<xref ref-type="fig" rid="fig8">Figure 8D</xref>). In a complementary experiment, we inhibited the PGE<sub>2</sub> receptors EP2 and EP4 prior to exposure of BMDMs to Wnt CM and IL-4. The results showed that control BMDMs had increased <italic>Arg1</italic> expression upon treatment with Wnt3a+IL-4 or CM+IL-4 (compared with IL-4 alone), with similar responses in BMDMs pre-treated with either EP2 or EP4 inhibitors (<xref ref-type="fig" rid="fig8">Figure 8E</xref>). However, BMDMs in which both receptors were inhibited simultaneously did not show enhanced <italic>Arg1</italic> expression upon Wnt3a+IL-4 or CM+IL-4 treatment, but rather responded similarly to IL-4-only-treated cells (<xref ref-type="fig" rid="fig8">Figure 8E</xref>).</p><p>Finally, to determine whether Wnt inhibition in vivo may affect PGE<sub>2</sub> production, we examined the expression of <italic>Ptgs2</italic>, <italic>Ptges,</italic> and <italic>Hpgd</italic> in macrophages LCM-excised from plaques of control or LGK974-treated mice (as in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1I</xref>). Although expression of <italic>Ptgs2</italic> and <italic>Hpgd</italic> did not differ between the two groups, the expression of <italic>Ptges</italic> was reduced by 58% in the LGK974 group compared to controls (<xref ref-type="fig" rid="fig8">Figure 8F</xref>). Taken together, our data suggest that macrophages activated by the Wnt pathway produce and secrete PGE<sub>2</sub>, activating STAT3 in an autocrine/paracrine fashion, which subsequently cooperates with IL-4/STAT6 (<xref ref-type="fig" rid="fig8">Figure 8G</xref>). In atherosclerosis, this mechanism primes the response of plaque macrophages to IL-4 that accumulates in plaques during disease progression and together induce resolution of atherosclerosis.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We have previously shown that aggressive lowering of ApoB-containing lipoproteins leads to resolution of atherosclerosis in mice, a process characterized by decreases in plaque macrophages and their expression of inflammatory genes, and by increased expression of pro-resolving genes. Among these is <italic>Arg1</italic>, which, besides depriving substrate to damaging iNOS (<xref ref-type="bibr" rid="bib45">Munder, 2009</xref>), has been recently shown to be essential for the clearance of multiple apoptotic cells (<xref ref-type="bibr" rid="bib70">Yurdagul et al., 2020</xref>), an important process in inflammation resolution in plaques and in general (<xref ref-type="bibr" rid="bib34">Libby et al., 2014</xref>). The expression of <italic>Arg1</italic> and other pro-resolving genes (i.e., <italic>Ccl17</italic> and <italic>Socs1</italic>) is regulated by STAT6 (<xref ref-type="bibr" rid="bib64">Van Dyken and Locksley, 2013</xref>; <xref ref-type="bibr" rid="bib56">Rutschman et al., 2001</xref>), which is concordant with our recent demonstration that following lipid lowering monocytes recruited to plaques in a STAT6-dependent manner mediate resolution (<xref ref-type="bibr" rid="bib51">Rahman et al., 2017</xref>).</p><p>We now extend these findings to show the following: (1) IL-4 promotes the resolution of atherosclerosis, though its levels in progressing or resolving plaques are low and stable; (2) the source of IL-4 required for disease resolution is from cells that accumulate in plaques during disease progression and not cells recruited following lipid lowering; (3) although the IL-4/STAT6 pathway is needed for disease resolution, it requires Wnt signaling to potentiate full IL-4 responsiveness; (4) loss of Wnt signaling in plaque macrophages is associated with impaired atherosclerosis resolution in mice, consistent with premature coronary disease in people with a loss-of-function mutation in the Wnt co-receptor <italic>Lrp6</italic> (<xref ref-type="bibr" rid="bib42">Mani et al., 2007</xref>), and with the lower level of gene expression of Wnt targets in symptomatic versus asymptomatic human plaques; and (5) Wnt signaling induces the production and secretion of PGE<sub>2</sub> and activation of STAT3, which are required for the enhancement of IL-4-induced effects on expression of genes associated with inflammation resolution. These findings come from integrating results from multiple mouse atherosclerosis studies, with biochemical and bioinformatic data from in vivo and in vitro systems, including from human plaques.</p><p>These results suggest that IL-4 alone is not sufficient for atherosclerosis resolution and that Wnt signaling cooperates with IL-4 to enhance its induction of the expression of genes associated with inflammation resolution. Of note, the inability of IL-4/13 to independently mount a sufficient response in macrophages to promote tissue repair, which atherosclerosis is an example of, has been recently shown in other contexts, including in the lungs after helminth infection or in the gut after induction of colitis (<xref ref-type="bibr" rid="bib8">Bosurgi et al., 2017</xref>). Rather, recognition of apoptotic cells through the receptors MER proto-oncogene, tyrosine kinase (MerTK) and Axl receptor tyrosine kinase together with IL-4 was needed for this induction in these two models (<xref ref-type="bibr" rid="bib8">Bosurgi et al., 2017</xref>). Another relevant study showed that IL-4/13 collaborate with local tissue enhancers that amplify their response upon helminth infection (<xref ref-type="bibr" rid="bib44">Minutti et al., 2017</xref>). Deletion of these local enhancers caused a drastic impairment in the inflammatory response against parasites, although IL-4/13 levels were unaffected.</p><p>It is plausible that the need for tissue enhancers arises from relatively low tissue IL-4 concentrations, which is supported by our finding that plaques contain ~100 pg/mL IL-4 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), a concentration that is 100–200-fold lower than what is used in typical in vitro studies (e.g., <xref ref-type="bibr" rid="bib44">Minutti et al., 2017</xref>; <xref ref-type="bibr" rid="bib8">Bosurgi et al., 2017</xref>; <xref ref-type="bibr" rid="bib57">Sanin et al., 2018</xref>). Overall, the results from the other systems bear a striking resemblance to the scheme in <xref ref-type="fig" rid="fig8">Figure 8G</xref>, in which we posited that for full IL-4/STAT6 responsiveness plaque macrophages require a second signal, which, in the case of atherosclerosis, is engagement of the Wnt pathway that promotes the production of PGE<sub>2</sub> and STAT3 activation. Further support for a ‘two factor’ model of IL-4 responsiveness, in general, and Wnt being one such factor, in particular, also comes from a model of kidney injury and fibrosis, in which Wnt3a caused the activation of STAT3 and enhanced IL-4 responses (<xref ref-type="bibr" rid="bib21">Feng et al., 2018</xref>).</p><p>One caveat of this study is that it is possible that plaque progression is attenuated by the absence of IL-4 and IL-13, thereby making resolution harder to observe. Indeed, some previous studies reported less plaque progression in <italic>Apoe</italic><sup>-/-</sup><italic>Il4</italic><sup>-/-</sup> (<xref ref-type="bibr" rid="bib16">Davenport and Tipping, 2003</xref>) and <italic>Ldlr</italic><sup>-/-</sup><italic>Il4</italic><sup>-/-</sup> (<xref ref-type="bibr" rid="bib31">King et al., 2002</xref>) compared to IL-4-sufficient mice. In contrast, an elegant study from Binder and colleagues <xref ref-type="bibr" rid="bib10">Cardilo‐Reis et al., 2012</xref> demonstrated that <italic>Il13</italic>-deficiency <italic>enhanced</italic> atherosclerosis progression and that pharmacological treatment with IL-13 inhibited macrophage accumulation and promoted pro-resolving macrophage polarization in plaques. Notably, in the present study, substantial plaques are formed in <italic>Il4<sup>-/-</sup>Il13<sup>-/-</sup></italic> mice (average plaque size of 319,293 µm<sup>2</sup>; <xref ref-type="fig" rid="fig1">Figure 1C</xref>), and our previously published data have shown atherosclerosis regression in significantly smaller plaques (&lt;200,000 µm, <xref ref-type="bibr" rid="bib5">Basu et al., 2018</xref>; <xref ref-type="bibr" rid="bib59">Sharma et al., 2020</xref>). Taken together, these findings support our conclusion that IL-4 is required for resolution of atherosclerosis of plaques of the type we studied.</p><p>Wnt proteins are evolutionary ancient and are highly abundant and diverse. Despite many Wnt proteins, there are common transcriptional targets, allowing the assessment of the pathway activity with transcriptomic data. As noted earlier, we reported the upregulation of Wnt-responsive genes in resolving plaque macrophages in two independent mouse models of atherosclerosis resolution (<xref ref-type="bibr" rid="bib53">Ramsey et al., 2014</xref>). In the present study, we show in a third model, but now on a single-cell level, that resolving plaque macrophages have higher expressions of Wnt-regulated genes (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>). That this may be relevant to human atherosclerosis is supported by the data in <xref ref-type="fig" rid="fig4">Figure 4D–F</xref>, which indicate lower activity of the Wnt pathway in macrophages from symptomatic human plaques, compared with asymptomatic ones, and increased Wnt-responsive gene expression in PBMCs from humans placed on LDL cholesterol-lowering therapy after an acute coronary syndrome. In particular, after 3 months of treatment, there was a significant inverse correlation between the expression of the canonical Wnt-target gene, <italic>Axin2</italic>, and plaque size. The studies in mice (<xref ref-type="fig" rid="fig6">Figure 6</xref>) and humans (<xref ref-type="fig" rid="fig4">Figure 4D–F</xref> and the <italic>Lrp6</italic> mutation (<xref ref-type="bibr" rid="bib42">Mani et al., 2007</xref>) in the aggregate strongly support an inverse relationship between Wnt activity and atherosclerosis severity.</p><p>Turning to STAT3, our results demonstrate that it is downstream of Wnt and collaborates with IL-4/STAT6 to enhance IL-4-induced gene expression (<xref ref-type="fig" rid="fig7">Figure 7F</xref>). This is in accordance with the aforementioned report showing enhanced response of BMDMs to IL-4 following Wnt3a treatment via activation of STAT3 in a model of kidney injury (<xref ref-type="bibr" rid="bib21">Feng et al., 2018</xref>), as well as with the suggestion that STAT3 and STAT6 cooperate to increase <italic>Arg1</italic> gene expression (reviewed in <xref ref-type="bibr" rid="bib50">Pourcet and Pineda-Torra, 2013</xref>). We extended the findings in vitro to show in vivo that STAT3 activation appears to be deficient in plaques upon Wnt inhibition (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). STAT3 is a particularly interesting STAT family member due to its important contributions to both inflammatory and anti-inflammatory responses. The mechanisms by which STAT3 induces such diverse responses are still unclear, but will be crucial to understand in order to target the intended function. One possibility is that STAT3 works with other transcription factors that are engaged downstream of various receptors. For instance, it had been previously shown that STAT3 (activated by IL-6) and STAT6 (activated by IL-4) cooperate to enhance expression and secretion of cathepsins, to promote polarization of tumor-associated macrophages (<xref ref-type="bibr" rid="bib69">Yan et al., 2016</xref>) and enhance IL-4-induced gene expression (<xref ref-type="bibr" rid="bib41">Makita et al., 2015</xref>; <xref ref-type="bibr" rid="bib23">Fernando et al., 2014</xref>; <xref ref-type="fig" rid="fig7">Figure 7B, C</xref>). Our findings appear to be in a similar vein, in that Wnt3a-induced STAT3 activation collaborated with IL-4-induced STAT6 activation to enhance responsiveness to IL-4.</p><p>Our data further suggest that STAT3 is activated following Wnt stimulation via PGE<sub>2</sub> since the latter is produced by Wnt3a-treated BMDMs (<xref ref-type="fig" rid="fig8">Figure 8A</xref>) and has been shown to promote the phosphorylation of STAT3 in various cell types (<xref ref-type="bibr" rid="bib30">Jw et al., 2019</xref>; <xref ref-type="bibr" rid="bib12">Chun et al., 2010</xref>; <xref ref-type="bibr" rid="bib65">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Halpern et al., 2019</xref>). Wnt signaling promotes the production of PGE<sub>2</sub> through transcriptional regulation of <italic>Ptgs2</italic> (<xref ref-type="bibr" rid="bib3">Araki et al., 2003</xref>; <xref ref-type="bibr" rid="bib46">Nunez et al., 2011</xref>), with similar results shown in <xref ref-type="fig" rid="fig8">Figure 8C</xref>. However, Wnt transcriptional control of other enzymes that regulate PGE<sub>2</sub> levels is less known. Our data show that in vitro, Wnt3a promoted the expression not only of <italic>Ptgs2</italic>, but also <italic>Ptges</italic>, and decreased the expression of <italic>Hpgd</italic> (<xref ref-type="fig" rid="fig8">Figure 8C</xref>). Since PTGS2 and PTGES are needed for PGE<sub>2</sub> synthesis and HPGD degrades PGE<sub>2</sub>, the net effect of Wnt-induced gene expression would be expected to increase PGE<sub>2</sub> concentrations, which we observed (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Interestingly, in plaque macrophages, of the PGE<sub>2</sub>-regulating enzymes, only the expression of <italic>Ptges</italic> was decreased upon Wnt inhibition, indicating a potentially relatively greater contribution of this enzyme in vivo in Wnt-mediated atherosclerosis resolution. Further supporting that PGE<sub>2</sub> is an important intermediary between Wnt signaling and the amplification of IL-4 responses were the experiments in which PGE<sub>2</sub> blockade or inhibition of its receptors abrogated this amplification (<xref ref-type="fig" rid="fig8">Figure 8D, E</xref>). PGE<sub>2</sub> itself was previously shown to amplify IL-4-induced gene expression in macrophages (<xref ref-type="bibr" rid="bib57">Sanin et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Gao et al., 2016</xref>; <xref ref-type="bibr" rid="bib39">Luan et al., 2015</xref>).</p><p>To place the present results in a wider context, the involvement of PGE<sub>2</sub> receptors in the development of atherosclerosis was also studied previously. Initially, it was reported that inhibition of PGE<sub>2</sub> responses via deletion of its receptor EP4 (but not EP2) decreased early atherosclerosis burden (<xref ref-type="bibr" rid="bib4">Babaev et al., 2008</xref>). However, this study did not report a significant change in plaque macrophage content in EP2 or EP4-deficient conditions. Later reports showed that EP4 deficiency in bone marrow (<xref ref-type="bibr" rid="bib60">Tang et al., 2011</xref>) or myeloid cells (<xref ref-type="bibr" rid="bib63">Vallerie et al., 2016</xref>) caused an increase in plaque inflammation and macrophage content, without affecting diabetic atherosclerosis. These data, together with results presented here, indicate that engagement of the PGE<sub>2</sub> receptor EP4 in macrophages may be beneficial not only for dampening atherosclerosis progression, but also enhancing disease resolution. However, whether direct activation of the receptors for PGE<sub>2</sub> will enhance atherosclerosis resolution merits additional investigation.</p><p>Also deserving of further investigation is the source of Wnt. Moreover, though from our data in vitro, it is reasonable to propose that PGE<sub>2</sub> production following Wnt stimulation acts in an autocrine or paracrine manner. Extrapolation to the situation in vivo has not been established, but the human data presented in <xref ref-type="fig" rid="fig4">Figure 4E, F</xref> suggest a systemic increase in Wnt responsiveness since circulating immune cells showed higher expression of Wnt-responsive genes in patients whose plaques were regressing as assessed by imaging. Furthermore, based on our mouse results, it is plausible that Wnt production or its secretion had increased in these patients upon lipid lowering.</p><p>In conclusion, the present study provides new insights into the molecular pathways involved in resolution of atherosclerosis, which remains an important clinical goal. While our previous studies pointed to IL-4 as a polarizer of plaque macrophages to drive them towards inflammation resolution, we were surprised to discover that this cytokine is required, but not sufficient, and that Wnt signaling is needed as well. Given the human data cited above, the clinical relevance of our findings is also plausible. Thus, the demonstrated molecular mechanism suggests a potential therapeutic strategy to improve the resolution of atherosclerosis after lipid lowering, namely, by co-activation of the IL-4 and PGE<sub>2</sub> pathways in plaque macrophages.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Study design</title><p>This study aimed at determining molecular mechanisms upstream of STAT6 that promote atherosclerosis resolution. Mouse studies of atherosclerosis resolution were performed on the basis of LDLr deficiency (<italic>Ldlr<sup>-/-</sup>, Pcsk9</italic>-AAV (<xref ref-type="bibr" rid="bib48">Peled et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Bjørklund et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Roche-Molina et al., 2015</xref>) and Reversa <xref ref-type="bibr" rid="bib18">Feig et al., 2011a</xref>; <xref ref-type="bibr" rid="bib35">Lieu et al., 2003</xref>), with WD (100244; Dyets Inc) feeding for 16–20 weeks, followed by aggressive cholesterol lowering (using ApoB-ASO for <italic>Ldlr<sup>-/-</sup></italic> and <italic>Pcsk9</italic>-AAV or poly I:C injections for Reversa; <xref ref-type="bibr" rid="bib18">Feig et al., 2011a</xref>; <xref ref-type="bibr" rid="bib35">Lieu et al., 2003</xref>) with chow diet feeding, according to the protocol (number IA16-00494) approved by the Institutional Animal Care and Use Committee of the New York University School of Medicine. In the aortic transplant model (<xref ref-type="bibr" rid="bib51">Rahman et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Chereshnev et al., 2003</xref>), aortic arches from atherosclerotic (<italic>Ldlr</italic><sup>-/-</sup>/<italic>Apoe<sup>-</sup></italic><sup>/-</sup>) mice were intrapositioned with the abdominal aorta in recipient mice (<italic>Il4</italic><sup>-/-</sup><italic>Il3</italic><sup>-/-</sup>/<italic>Il4</italic><sup>-/-</sup>, maintained on a chow diet), and blood flow was directed through the graft. For in vivo Wnt inhibition studies, mice were administered 3 mg/kg LGK974 (<xref ref-type="bibr" rid="bib37">Liu et al., 2013</xref>) (S7143; Celleckchem) three times/week by oral gavage. For all studies, mice were randomized into the groups at the BL time point. Researchers were not blinded to the identity of the study groups, with blinding prior to data analysis. Based on a power analysis (performed as described on <ext-link ext-link-type="uri" xlink:href="https://stats.idre.ucla.edu/">https://stats.idre.ucla.edu/</ext-link>other/mult-pkg/seminars/intro-power/), we typically enroll 15 mice to have at minimum 10 mice/group; this is estimated to give 90% power to detect differences greater than 20% in atherosclerotic plaque parameters with ≈15% standard deviation between wild type and test mice based on two-sided two-sample <italic>t</italic>-test with α = 0.05. In some cases, fewer mice were used in order to have enough tissues for all of the sample types needed.</p></sec><sec id="s4-2"><title>Animals</title><p>C57BL/6, <italic>Il4</italic><sup>-/-</sup>, <italic>Stat6</italic><sup>-/-</sup>, <italic>Apoe</italic><sup>-/-</sup>, <italic>Ldlr</italic><sup>-/-</sup>, and Reversa mice were purchased from The Jackson Laboratory. <italic>Il4<sup>-/-</sup>Il13<sup>-/-</sup></italic>mice (C57BL6/J background) were provided by Dr. Thomas Wynn (then at the National Institutes of Health). IL-4/eGFP mice were provided by Dr. Richard Locksley (University of California San Francisco). Male and female mice at ages 6–10 weeks were used.</p></sec><sec id="s4-3"><title>Pcsk9 AAV model</title><p>This new atherosclerosis resolution model was recently described (<xref ref-type="bibr" rid="bib48">Peled et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Bjørklund et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Roche-Molina et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Sharma et al., 2020</xref>). Briefly, mice were injected intraperitoneally with an AAV that expresses a hyperactive form of <italic>Pcsk9</italic> (AAV.8TBGmPCSK9D377Y, Penn Vector Core), under the regulation of a liver-specific promoter, at 1 × 10<sup>12</sup> viral particles/mouse. After 16–20 weeks of WD feeding, lipid lowering was achieved by discontinuing the WD feeding and bi-weekly i.p. injections of 50 mg/kg ASO to ApoB, kindly provided by Ionis Pharmaceuticals. Mice were sacrificed after 3 weeks of ApoB ASO treatment and their tissues collected.</p></sec><sec id="s4-4"><title>Human specimens</title><p>For the data displayed in <xref ref-type="fig" rid="fig4">Figure 4D</xref>, they were based on the initial analysis of human atherosclerosis samples as previously reported (<xref ref-type="bibr" rid="bib22">Fernandez et al., 2019</xref>). Subjects gave informed written consent, following the approval by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai (IRB 11-01427). For the data displayed in <xref ref-type="fig" rid="fig4">Figure 4E, F</xref>, the examination of atherosclerosis resolution features in humans was described previously (<xref ref-type="bibr" rid="bib1">Alkhalil et al., 2018</xref>). Ethical approval was obtained from National Research Ethics Services (NRES) and Oxford R and D committee prior to commencement of the study. All patients provided written informed consent prior to participation in this study, which included the collection of peripheral blood cells and their analysis.</p></sec><sec id="s4-5"><title>Plaque morphometrics and immunohistochemistry</title><p>Hearts were removed after perfusion at physiological pressure of saline containing 10% sucrose, embedded in OCT, and frozen. Hearts were sectioned through the aortic root (6 μm) and stained for CD68 (MCA1957; AbD Serotec) to detect macrophages, active-β-catenin (8814; Cell Signaling Technology), STAT3 (8768; Cell Signaling Technology), MRC1 (MCA2235; AbD Serotec), ARG1 (sc-20150; Santa Cruz), VCAM1 (ab134047; Abcam), and CCL2 (505908; BioLegend). Picrosirius red was used for collagen staining, and imaging done using polarizing light microscopy. Image analysis was performed with ImagePro Plus 7.0 software (Media Cybernetics) and ImageJ (National Institute of Health <xref ref-type="bibr" rid="bib58">Schneider et al., 2012</xref>).</p></sec><sec id="s4-6"><title>Flow cytometry</title><p>Aortic arches were digested as previously described (<xref ref-type="bibr" rid="bib61">Tang et al., 2015</xref>), after their dissection following perfusion with PBS. Single-cell suspensions were added a live/dead cell staining (L23105; Invitrogen) and PE-Cy7 anti-CD45 antibody (103132; Biolegend) and analyzed using the LSRII cytometer (BD Biosciences).</p></sec><sec id="s4-7"><title>Plaque cytokine measurement</title><p>Plaques from <italic>Ldlr<sup>-/-</sup></italic> mice fed WD for 20 weeks and treated or not with ApoB ASO for 3 weeks were carefully scraped out from the aortic wall, placed in a tube containing 100 μL PBS and protease/phosphatase inhibitor (A32961, Thermo Fisher Scientific) and weighed. Plaques were manually homogenized until no pieces were apparent (~2 min). Concentrations of CCL2, IL-4, and IL-13 in suspensions were measured using a custom mouse LEGENDplex assay (Biolegend).</p></sec><sec id="s4-8"><title>Bone marrow-derived macrophages</title><p>Bone marrow was harvested from the femur and tibia of 6–20-week-old mice and treated with red-blood cell lysis buffer (R7757; Sigma-Aldrich) for 5 min. After washing, cells were seeded in DMEM media supplemented with 10% FBS, 1% penicillin/streptomycin, and 10 ng/mL macrophage colony-stimulating factor (m-CSF) (315-02; PeproTech). Cells were supplemented with media every other day and used for experiments between day 5 and 10 post harvest. Cells were typically treated with 100 ng/mL Wnt3a (1324-WN-010/CF; R&amp;D Systems), 100 pg/mL IL-4, 5 ng/mL IL-6, and 2.5 ng/mL IL-10 (214-14, 216-16, and 210-10, respectively; Peprotech) for 16 hr, unless indicated otherwise. Experiments with Wnt CM or 100 pg/mL PGE<sub>2</sub> (14010; Cyaman Chemical) include treatment with IL-4 for 2.5 hr. For experiments with siRNA, BMDMs were transfected overnight with 25 nM scrambled (control) or STAT3 siRNA (L-040794-01; Dharmacon) using Lipofectamine RNAiMax Transfection reagent (13778075; Thermo Fisher Scientific), and started on Wnt3a and IL-4 treatments 48 hr after transfection. Blocking antibodies and protein inhibitors were used in the following concentrations: 0.5 µg/mL anti-TGFβ (521707; Biolegend), 0.1 µg/mL anti-gp130 from (MAB4682; R&amp;D Systems), 1 µg/mL anti-HGFR (AF527; R&amp;D Systems), 10 µg/mL anti-IL10R (112707; Biolegend), 0.1 µM AMG487 CXCR3 inhibitor (4487; Tocris Bioscience), 1 µg/mL anti-Wnt3a (MAB9025; R&amp;D Systems), 100 nM anti-PGE<sub>2</sub> (10009814; Cayman Chemical), 30 µM AH6809 EP2 inhibitor (14050; Cayman Chemical), and 30 µM GW627368X EP4 inhibitor (10009162; Cayman Chemical).</p></sec><sec id="s4-9"><title>Laser capture microdissection</title><p>Under strict RNAse-free conditions, aortic root sections were stained with hematoxylin-eosin and captured. RNA was then isolated using the PicoPure Kit (KIT0204; Thermo Fisher Scientific), and quality and quantity were determined using an Agilent 2100 Bioanalyzer (5067-1513; Agilent Technologies). RNA was converted to cDNA and amplified using the WT-Ovation Pico RNA Amplification Kit (3302-12; NuGEN) (<xref ref-type="bibr" rid="bib53">Ramsey et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Feig et al., 2012</xref>; <xref ref-type="bibr" rid="bib62">Trogan et al., 2002</xref>).</p></sec><sec id="s4-10"><title>Real-time qPCR</title><p>Total RNA was isolated using TRIzol reagent (15596-018; Life Technologies) and Direct-zol RNA MiniPrep columns (R2052; Zymo Research) and quantified using Nanodrop 2000 (Nanodrop Products). Quantitative real-time PCR was performed using FAST SYBR Green Master Mix (4385612; Applied Biosystems) on the ABI PRISM 7300 sequence detection system (Applied Biosystems). The mRNA levels were normalized to <italic>Gapdh</italic> or <italic>Hprt</italic> as reference genes. Primer sequences are available in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-11"><title>Human PBMC analysis of Wnt-responsive genes</title><p>RNA was isolated from PBMCs collected from patients in the study in reference (<xref ref-type="bibr" rid="bib1">Alkhalil et al., 2018</xref>), and the expression of Wnt target genes (<italic>Axin2, Ddx3x, Wls, Senp2, Ctnnb1, Csnk1a1,</italic> and <italic>Amfr</italic>) was measured by RT-PCR, with 18S RNA as a reference. Imaging of carotid atherosclerotic plaques was performed as described in <xref ref-type="bibr" rid="bib1">Alkhalil et al., 2018</xref>.</p></sec><sec id="s4-12"><title>RNAseq analysis</title><p>BMDMs were treated with media (untreated), Wnt3a, IL-4 ,and Wnt3a+IL-4 for 16 hr. RNA was isolated as described above. Single-read RNA sequencing was performed using the Illumina HiSeq 2500. All samples had high quality, when checked with FastQC v0.11.7 (<ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>). Illumina adapter sequences and poor-quality bases were trimmed using trimmomatic v0.36 (<xref ref-type="bibr" rid="bib7">Bolger et al., 2014</xref>). Trimmed sequences were mapped to the mm10 mouse reference genome using STAR v2.6.0a (<xref ref-type="bibr" rid="bib17">Dobin et al., 2013</xref>), indexed using samtools v1.9 (<xref ref-type="bibr" rid="bib32">Li et al., 2009</xref>), then quantified for UCSC genes using HTSeq-count v0.11.1 (<xref ref-type="bibr" rid="bib2">Anders et al., 2015</xref>). Comparative analysis between conditions was performed using DESeq2 v1.24.0 (<xref ref-type="bibr" rid="bib38">Love et al., 2014</xref>) with default parameters. PCA was performed on the RNA (19,862 transcripts) dataset using PCA function in MATLAB (R2017a).</p></sec><sec id="s4-13"><title>Feature and violin plots</title><p>We summed the expression values of genes associated with the GO term GO:0016055 (Wnt signaling pathway), added the summed expression as a metadata feature using Seurat, and plotted the expression in UMAP using Seurat FeaturePlot. We also plotted the level of summed Wnt expression for each cell, summarized as a violin plot, and split by treatment group. Significance was assessed using the Wilcoxon rank-sum test within each cluster between groups.</p></sec><sec id="s4-14"><title>Heat map</title><p>For each of gene associated with GO:0016055, we calculated a log fold-change (logFC) value for resolution/progression for each cluster using the Seurat FindMarkers function. We then performed hierarchical clustering based on the gene logFC values and visualized them using pheatmap.</p></sec><sec id="s4-15"><title>Human plaque macrophage analysis</title><p>The sum and average of the logFC across macrophage clusters in the mouse dataset were analyzed for GO:0016055. The top 10 genes with the highest sum were the same as the top 10 genes with the highest average, and these genes were chosen for further analysis. LogFC was calculated for symptomatic versus asymptomatic patients. To determine the significance of the enrichment for negative logFC values (symptomatic/asymptomatic) in the subset of 10 Wnt responsive genes, we calculated logFC values (symptomatic/asymptomatic) for all genes in the dataset and ran a permutation test with 10,000 permutations. Specifically, for each of the permutations, we randomly selected 10 genes from the set of all genes and recorded the number of negative logFC values in that random selection. p-Values were calculated as the fraction of permutations that yielded seven or more negative logFC values. Human studies consent was obtained as described in <xref ref-type="bibr" rid="bib22">Fernandez et al., 2019</xref>; <xref ref-type="bibr" rid="bib1">Alkhalil et al., 2018</xref>.</p></sec><sec id="s4-16"><title>Western blotting</title><p>BMDM lysates were run in 12% SDS-polyacrylamide gels under denaturing conditions and blots were stained with anti-pY-STAT3 (9131;Cell Signaling Technology), anti-total-STAT3 (8768; Cell Signaling Technology), β-catenin (sc-7963; Santa Cruz), and anti-GAPDH antibodies (G8795; Sigma-Aldrich). Immunoreactive bands were visualized using the Odyssey imaging system (LI-COR Biosciences) by using horseradish peroxidase-conjugated secondary antibodies (ab205718; Abcam and 626520; Thermo Fisher Scientific) and chemiluminescence.</p></sec><sec id="s4-17"><title>Targeted liquid chromatography-tandem mass spectrometry</title><p>Media of BMDMs treated with Wnt3a was immediately added to two volumes of ice-cold methanol and stored at −80°C (<xref ref-type="bibr" rid="bib15">Dalli et al., 1730</xref>). Prior to solid phase extraction, 500 pg of deuterated synthetic standards (d5-RvD2, d5-LXA<sub>4</sub>, d4-LTB<sub>4</sub>, and d4-PGE<sub>2</sub>; Cayman Chemical) were added to the samples. Samples were centrifuged (3000 rpm for 10 min at 4°C) and supernatants collected, acidified to pH 3.5, and extracted using C18 cartridges (Biotage). Finally, lipid mediators were eluted from the column by addition of methyl formate. The solvent was then evaporated under N<sub>2</sub> gas. Samples were resuspended in a 1:1 mixture of methanol and water and subjected to LC-MS/MS analysis using a Poroshell reverse-phase C18 column (100 mm × 4.6 mm × 2.7 µm; Agilent Technologies) equipped high-performance liquid chromatography system (Shimadzu) coupled to a QTrap 5500 mass-spectrometer (AB Sciex) operating in negative ionization mode. Scheduled multiple reaction monitoring (MRM) transitions coupled with information-dependent acquisition and enhanced product ion-scanning was used thereafter. Specific lipid mediators were identified by matching their retention time and at least six diagnostic MS/MS ions, compared with external standards (Cayman Chemical) analyzed in parallel. For quantification, the MRM peak was compared with synthetic standards. Extraction recovery was determined using the internal deuterated standards added to the samples prior to extraction.</p></sec><sec id="s4-18"><title>Statistical analysis</title><p>GraphPad Prism 7 (GraphPad Software) was used for statistical analysis. Data are expressed as mean ± SEM. With three or more groups, statistical analysis was performed using one-way ANOVA, with Dunnett’s multiple comparisons testing and Gaussian distribution. Comparison of two parameters for two or more groups was performed using a two-way ANOVA, with Sidak’s multiple comparison testing. Data involving comparisons between two groups were analyzed using two-tailed <italic>t</italic>-test. p&lt;0.05 was considered significant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Drs. Thomas Wynn and Richard Locksley for providing mice used in this study. We also thank Mark Graham and Richard Lee (Ionis Pharmaceuticals) for graciously providing the ApoB ASO. SPH is supported by the NIH (K23HL135398). CG is supported by the American Heart Association (AHA, 20SFRN35210252) and the NIH (R03HL13528, K23HL111339, R21TR001739, UH2/3TR002067). DF is supported by NIH training grant 5T23HL007824. MS acknowledges the support of NIH grants HL106173 and GM095467. BES was supported by a National Research Service Award from the NIH (HL136044). This research was supported in part by the Intramural Research Program of the NIH to PL, as well as NIH grants AI130945, AI133977, HL084312, and U.S. Department of Defense (DoD) award W81XWH-16-1-0256. EAF acknowledges support from NIH grants HL084312 and DoD award W81XWH-16-1-0256. AW was supported by the AHA (18POST34080390) and the NIH (K99HL151963). KR was supported by NIH training grants T32GM007308 and T32AI100853, and NIH fellowship F30HL131183.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con10"><p>Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Methodology</p></fn><fn fn-type="con" id="con12"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con13"><p>Investigation</p></fn><fn fn-type="con" id="con14"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con15"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con16"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con17"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Data curation, Supervision</p></fn><fn fn-type="con" id="con19"><p>Data curation, Formal analysis, Supervision, Methodology</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Supervision, Investigation, Methodology</p></fn><fn fn-type="con" id="con21"><p>Conceptualization, Data curation, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con22"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Methodology, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to the protocol (number IA16-00494) approved by the Institutional Animal Care and Use Committee of the New York University School of Medicine.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>qPCR primer sequences.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-67932-supp1-v3.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-67932-transrepform-v3.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>The RNA sequencing data are deposited in GEO under accession number GSE168542.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Weinstock</surname><given-names>A</given-names></name><name><surname>Ruggles</surname><given-names>KV</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Wnt signaling enhances macrophage responses to IL-4 and promotes resolution of atherosclerosis</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE168542">GSE168542</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>DM</given-names></name><name><surname>Rahman</surname><given-names>AH</given-names></name><name><surname>Fernandez</surname><given-names>N</given-names></name><name><surname>Chudnovskiy</surname><given-names>A</given-names></name><name><surname>Amir</surname><given-names>ED</given-names></name><name><surname>Amadori</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>NS</given-names></name><name><surname>Wong</surname><given-names>CK</given-names></name><name><surname>Shamailova</surname><given-names>R</given-names></name><name><surname>Hill</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Remark</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>JR</given-names></name><name><surname>Pina</surname><given-names>C</given-names></name><name><surname>Faries</surname><given-names>C</given-names></name><name><surname>Awad</surname><given-names>AJ</given-names></name><name><surname>Moss</surname><given-names>N</given-names></name><name><surname>Bjorkegren</surname><given-names>JLM</given-names></name><name><surname>Kim-Schulze</surname><given-names>S</given-names></name><name><surname>Gnjatic</surname><given-names>S</given-names></name><name><surname>Ma'ayan</surname><given-names>A</given-names></name><name><surname>Mocco</surname><given-names>J</given-names></name><name><surname>Faries</surname><given-names>P</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Giannarelli</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Single-cell immune landscape of human atherosclerotic plaques</data-title><source>Zenodo</source><pub-id assigning-authority="Zenodo" pub-id-type="doi">10.5281/zenodo.3361716</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Nishi</surname><given-names>H</given-names></name><name><surname>Poles</surname><given-names>J</given-names></name><name><surname>Niu</surname><given-names>X</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name><name><surname>Ramsey</surname><given-names>SA</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name><name><surname>Loke</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Single-cell analysis of fate-mapped macrophages reveals heterogeneity, including stem-like properties, during atherosclerosis progression and regression</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123587">GSE123587</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Schlegel</surname><given-names>PM</given-names></name><name><surname>Afonso</surname><given-names>MS</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name><name><surname>Rahman</surname><given-names>K</given-names></name><name><surname>Weinstock</surname><given-names>A</given-names></name><name><surname>Sansbury</surname><given-names>BE</given-names></name><name><surname>Corr</surname><given-names>EM</given-names></name><name><surname>van</surname><given-names>Solingen C</given-names></name><name><surname>Koelwyn</surname><given-names>GJ</given-names></name><name><surname>Shanley</surname><given-names>LC</given-names></name><name><surname>Beckett</surname><given-names>L</given-names></name><name><surname>Peled</surname><given-names>D</given-names></name><name><surname>Lafaille</surname><given-names>JJ</given-names></name><name><surname>Spite</surname><given-names>M</given-names></name><name><surname>Loke</surname><given-names>P</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name><name><surname>Moore</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Regulatory T cells license macrophage pro-resolving functions in atherosclerosis regression</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE141038">GSE141038</pub-id></element-citation></p><p><element-citation id="dataset5" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Sanin</surname><given-names>DE</given-names></name><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Geltink</surname><given-names>RIK</given-names></name><name><surname>Grzes</surname><given-names>KM</given-names></name><name><surname>van</surname><given-names>Teijlingen Bakker N</given-names></name><name><surname>Corrado</surname><given-names>M</given-names></name><name><surname>Kabat</surname><given-names>AM</given-names></name><name><surname>Buck</surname><given-names>MD</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name><name><surname>Lawless</surname><given-names>SJ</given-names></name><name><surname>Cameron</surname><given-names>AM</given-names></name><name><surname>Villa</surname><given-names>M</given-names></name><name><surname>Baixauli</surname><given-names>F</given-names></name><name><surname>Patterson</surname><given-names>AE</given-names></name><name><surname>Hässler</surname><given-names>F</given-names></name><name><surname>Curtis</surname><given-names>JD</given-names></name><name><surname>O’Neill</surname><given-names>CM</given-names></name><name><surname>O’Sullivan</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Mittler</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>SC</given-names></name><name><surname>Pearce</surname><given-names>EL</given-names></name><name><surname>Pearce</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Mitochondrial Membrane Potential Regulates Nuclear Gene Expression in Macrophages Exposed to PGE2 (RNA-seq)</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119509">GSE119509</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkhalil</surname> <given-names>M</given-names></name><name><surname>Biasiolli</surname> <given-names>L</given-names></name><name><surname>Akbar</surname> <given-names>N</given-names></name><name><surname>Galassi</surname> <given-names>F</given-names></name><name><surname>Chai</surname> <given-names>JT</given-names></name><name><surname>Robson</surname> <given-names>MD</given-names></name><name><surname>Choudhury</surname> <given-names>RP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>T2 mapping MRI technique quantifies carotid plaque lipid, and its depletion after statin initiation, following acute myocardial infarction</article-title><source>Atherosclerosis</source><volume>279</volume><fpage>100</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2018.08.033</pub-id><pub-id pub-id-type="pmid">30227984</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname> <given-names>S</given-names></name><name><surname>Pyl</surname> <given-names>PT</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HTSeq--a Python framework to work with high-throughput sequencing data</article-title><source>Bioinformatics</source><volume>31</volume><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu638</pub-id><pub-id pub-id-type="pmid">25260700</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araki</surname> <given-names>Y</given-names></name><name><surname>Okamura</surname> <given-names>S</given-names></name><name><surname>Hussain</surname> <given-names>SP</given-names></name><name><surname>Nagashima</surname> <given-names>M</given-names></name><name><surname>He</surname> <given-names>P</given-names></name><name><surname>Shiseki</surname> <given-names>M</given-names></name><name><surname>Miura</surname> <given-names>K</given-names></name><name><surname>Harris</surname> <given-names>CC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Regulation of cyclooxygenase-2 expression by the wnt and ras pathways</article-title><source>Cancer Research</source><volume>63</volume><fpage>728</fpage><lpage>734</lpage><pub-id pub-id-type="pmid">12566320</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babaev</surname> <given-names>VR</given-names></name><name><surname>Chew</surname> <given-names>JD</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Davis</surname> <given-names>S</given-names></name><name><surname>Breyer</surname> <given-names>MD</given-names></name><name><surname>Breyer</surname> <given-names>RM</given-names></name><name><surname>Oates</surname> <given-names>JA</given-names></name><name><surname>Fazio</surname> <given-names>S</given-names></name><name><surname>Linton</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis</article-title><source>Cell Metabolism</source><volume>8</volume><fpage>492</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2008.09.005</pub-id><pub-id pub-id-type="pmid">19041765</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname> <given-names>D</given-names></name><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Huggins</surname> <given-names>LA</given-names></name><name><surname>Mullick</surname> <given-names>AE</given-names></name><name><surname>Graham</surname> <given-names>MJ</given-names></name><name><surname>Wietecha</surname> <given-names>T</given-names></name><name><surname>Barnhart</surname> <given-names>S</given-names></name><name><surname>Mogul</surname> <given-names>A</given-names></name><name><surname>Pfeiffer</surname> <given-names>K</given-names></name><name><surname>Zirlik</surname> <given-names>A</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name><name><surname>Bornfeldt</surname> <given-names>KE</given-names></name><name><surname>Willecke</surname> <given-names>F</given-names></name><name><surname>Goldberg</surname> <given-names>IJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Novel reversible model of atherosclerosis and regression using oligonucleotide regulation of the LDL receptor</article-title><source>Circulation Research</source><volume>122</volume><fpage>560</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.311361</pub-id><pub-id pub-id-type="pmid">29321129</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjørklund</surname> <given-names>MM</given-names></name><name><surname>Hollensen</surname> <given-names>AK</given-names></name><name><surname>Hagensen</surname> <given-names>MK</given-names></name><name><surname>Dagnaes-Hansen</surname> <given-names>F</given-names></name><name><surname>Christoffersen</surname> <given-names>C</given-names></name><name><surname>Mikkelsen</surname> <given-names>JG</given-names></name><name><surname>Bentzon</surname> <given-names>JF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Induction of atherosclerosis in mice and hamsters without germline genetic engineering</article-title><source>Circulation Research</source><volume>114</volume><fpage>1684</fpage><lpage>1689</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.302937</pub-id><pub-id pub-id-type="pmid">24677271</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname> <given-names>AM</given-names></name><name><surname>Lohse</surname> <given-names>M</given-names></name><name><surname>Usadel</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Trimmomatic: a flexible trimmer for illumina sequence data</article-title><source>Bioinformatics</source><volume>30</volume><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmid">24695404</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosurgi</surname> <given-names>L</given-names></name><name><surname>Cao</surname> <given-names>YG</given-names></name><name><surname>Cabeza-Cabrerizo</surname> <given-names>M</given-names></name><name><surname>Tucci</surname> <given-names>A</given-names></name><name><surname>Hughes</surname> <given-names>LD</given-names></name><name><surname>Kong</surname> <given-names>Y</given-names></name><name><surname>Weinstein</surname> <given-names>JS</given-names></name><name><surname>Licona-Limon</surname> <given-names>P</given-names></name><name><surname>Schmid</surname> <given-names>ET</given-names></name><name><surname>Pelorosso</surname> <given-names>F</given-names></name><name><surname>Gagliani</surname> <given-names>N</given-names></name><name><surname>Craft</surname> <given-names>JE</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name><name><surname>Ghosh</surname> <given-names>S</given-names></name><name><surname>Rothlin</surname> <given-names>CV</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells</article-title><source>Science</source><volume>356</volume><fpage>1072</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1126/science.aai8132</pub-id><pub-id pub-id-type="pmid">28495875</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyle</surname> <given-names>JJ</given-names></name><name><surname>Weissberg</surname> <given-names>PL</given-names></name><name><surname>Bennett</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>23</volume><fpage>1553</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000086961.44581.B7</pub-id><pub-id pub-id-type="pmid">12869351</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardilo‐Reis</surname> <given-names>L</given-names></name><name><surname>Gruber</surname> <given-names>S</given-names></name><name><surname>Schreier</surname> <given-names>SM</given-names></name><name><surname>Drechsler</surname> <given-names>M</given-names></name><name><surname>Papac‐Milicevic</surname> <given-names>N</given-names></name><name><surname>Weber</surname> <given-names>C</given-names></name><name><surname>Wagner</surname> <given-names>O</given-names></name><name><surname>Stangl</surname> <given-names>H</given-names></name><name><surname>Soehnlein</surname> <given-names>O</given-names></name><name><surname>Binder</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Interleukin‐13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype</article-title><source>EMBO Molecular Medicine</source><volume>4</volume><fpage>1072</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1002/emmm.201201374</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chereshnev</surname> <given-names>I</given-names></name><name><surname>Trogan</surname> <given-names>E</given-names></name><name><surname>Omerhodzic</surname> <given-names>S</given-names></name><name><surname>Itskovich</surname> <given-names>V</given-names></name><name><surname>Aguinaldo</surname> <given-names>J-G</given-names></name><name><surname>Fayad</surname> <given-names>ZA</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name><name><surname>Reis</surname> <given-names>ED</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Mouse model of heterotopic aortic arch transplantation</article-title><source>Journal of Surgical Research</source><volume>111</volume><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/S0022-4804(03)00039-8</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname> <given-names>K-S</given-names></name><name><surname>Lao</surname> <given-names>H-C</given-names></name><name><surname>Langenbach</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G Protein-dependent and β-Arrestin1-dependent signaling pathways</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>39672</fpage><lpage>39681</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.117689</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Combadière</surname> <given-names>C</given-names></name><name><surname>Potteaux</surname> <given-names>S</given-names></name><name><surname>Rodero</surname> <given-names>M</given-names></name><name><surname>Simon</surname> <given-names>T</given-names></name><name><surname>Pezard</surname> <given-names>A</given-names></name><name><surname>Esposito</surname> <given-names>B</given-names></name><name><surname>Merval</surname> <given-names>R</given-names></name><name><surname>Proudfoot</surname> <given-names>A</given-names></name><name><surname>Tedgui</surname> <given-names>A</given-names></name><name><surname>Mallat</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C hi and Ly6C loMonocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice</article-title><source>Circulation</source><volume>117</volume><fpage>1649</fpage><lpage>1657</lpage></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cybulsky</surname> <given-names>MI</given-names></name><name><surname>Iiyama</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Zhu</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>M</given-names></name><name><surname>Iiyama</surname> <given-names>M</given-names></name><name><surname>Davis</surname> <given-names>V</given-names></name><name><surname>Gutierrez-Ramos</surname> <given-names>J-C</given-names></name><name><surname>Connelly</surname> <given-names>PW</given-names></name><name><surname>Milstone</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>A major role for VCAM-1, but not ICAM-1, in early atherosclerosis</article-title><source>Journal of Clinical Investigation</source><volume>107</volume><fpage>1255</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1172/JCI11871</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalli</surname> <given-names>J</given-names></name><name><surname>Colas</surname> <given-names>RA</given-names></name><name><surname>Walker</surname> <given-names>ME</given-names></name><name><surname>Serhan</surname> <given-names>CN</given-names></name></person-group><year iso-8601-date="1730">1730</year><article-title>Lipid Mediator Metabolomics Via LC-MS/MS Profiling and Analysis</article-title><source>Methods Mol Biol</source><volume>2018</volume><fpage>59</fpage><lpage>72</lpage></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davenport</surname> <given-names>P</given-names></name><name><surname>Tipping</surname> <given-names>PG</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice</article-title><source>The American Journal of Pathology</source><volume>163</volume><fpage>1117</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63471-2</pub-id><pub-id pub-id-type="pmid">12937153</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname> <given-names>A</given-names></name><name><surname>Davis</surname> <given-names>CA</given-names></name><name><surname>Schlesinger</surname> <given-names>F</given-names></name><name><surname>Drenkow</surname> <given-names>J</given-names></name><name><surname>Zaleski</surname> <given-names>C</given-names></name><name><surname>Jha</surname> <given-names>S</given-names></name><name><surname>Batut</surname> <given-names>P</given-names></name><name><surname>Chaisson</surname> <given-names>M</given-names></name><name><surname>Gingeras</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feig</surname> <given-names>JE</given-names></name><name><surname>Parathath</surname> <given-names>S</given-names></name><name><surname>Rong</surname> <given-names>JX</given-names></name><name><surname>Mick</surname> <given-names>SL</given-names></name><name><surname>Vengrenyuk</surname> <given-names>Y</given-names></name><name><surname>Grauer</surname> <given-names>L</given-names></name><name><surname>Young</surname> <given-names>SG</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2011">2011a</year><article-title>Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques</article-title><source>Circulation</source><volume>123</volume><fpage>989</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.984146</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feig</surname> <given-names>JE</given-names></name><name><surname>Rong</surname> <given-names>JX</given-names></name><name><surname>Shamir</surname> <given-names>R</given-names></name><name><surname>Sanson</surname> <given-names>M</given-names></name><name><surname>Vengrenyuk</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Rayner</surname> <given-names>K</given-names></name><name><surname>Moore</surname> <given-names>K</given-names></name><name><surname>Garabedian</surname> <given-names>M</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2011">2011b</year><article-title>HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells</article-title><source>PNAS</source><volume>108</volume><fpage>7166</fpage><lpage>7171</lpage><pub-id pub-id-type="doi">10.1073/pnas.1016086108</pub-id><pub-id pub-id-type="pmid">21482781</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feig</surname> <given-names>JE</given-names></name><name><surname>Vengrenyuk</surname> <given-names>Y</given-names></name><name><surname>Reiser</surname> <given-names>V</given-names></name><name><surname>Wu</surname> <given-names>C</given-names></name><name><surname>Statnikov</surname> <given-names>A</given-names></name><name><surname>Aliferis</surname> <given-names>CF</given-names></name><name><surname>Garabedian</surname> <given-names>MJ</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name><name><surname>Puig</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e39790</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0039790</pub-id><pub-id pub-id-type="pmid">22761902</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>Y</given-names></name><name><surname>Ren</surname> <given-names>J</given-names></name><name><surname>Gui</surname> <given-names>Y</given-names></name><name><surname>Wei</surname> <given-names>W</given-names></name><name><surname>Shu</surname> <given-names>B</given-names></name><name><surname>Lu</surname> <given-names>Q</given-names></name><name><surname>Xue</surname> <given-names>X</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>He</surname> <given-names>W</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Dai</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Wnt/<italic>β</italic>-Catenin-Promoted Macrophage Alternative Activation Contributes to Kidney Fibrosis</article-title><source>Journal of the American Society of Nephrology</source><volume>29</volume><fpage>182</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1681/ASN.2017040391</pub-id><pub-id pub-id-type="pmid">29021383</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname> <given-names>DM</given-names></name><name><surname>Rahman</surname> <given-names>AH</given-names></name><name><surname>Fernandez</surname> <given-names>NF</given-names></name><name><surname>Chudnovskiy</surname> <given-names>A</given-names></name><name><surname>Amir</surname> <given-names>ED</given-names></name><name><surname>Amadori</surname> <given-names>L</given-names></name><name><surname>Khan</surname> <given-names>NS</given-names></name><name><surname>Wong</surname> <given-names>CK</given-names></name><name><surname>Shamailova</surname> <given-names>R</given-names></name><name><surname>Hill</surname> <given-names>CA</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Remark</surname> <given-names>R</given-names></name><name><surname>Li</surname> <given-names>JR</given-names></name><name><surname>Pina</surname> <given-names>C</given-names></name><name><surname>Faries</surname> <given-names>C</given-names></name><name><surname>Awad</surname> <given-names>AJ</given-names></name><name><surname>Moss</surname> <given-names>N</given-names></name><name><surname>Bjorkegren</surname> <given-names>JLM</given-names></name><name><surname>Kim-Schulze</surname> <given-names>S</given-names></name><name><surname>Gnjatic</surname> <given-names>S</given-names></name><name><surname>Ma'ayan</surname> <given-names>A</given-names></name><name><surname>Mocco</surname> <given-names>J</given-names></name><name><surname>Faries</surname> <given-names>P</given-names></name><name><surname>Merad</surname> <given-names>M</given-names></name><name><surname>Giannarelli</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single-cell immune landscape of human atherosclerotic plaques</article-title><source>Nature Medicine</source><volume>25</volume><fpage>1576</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0590-4</pub-id><pub-id pub-id-type="pmid">31591603</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernando</surname> <given-names>MR</given-names></name><name><surname>Reyes</surname> <given-names>JL</given-names></name><name><surname>Iannuzzi</surname> <given-names>J</given-names></name><name><surname>Leung</surname> <given-names>G</given-names></name><name><surname>McKay</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e94188</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0094188</pub-id><pub-id pub-id-type="pmid">24736635</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Jin</surname> <given-names>R</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name><name><surname>Ge</surname> <given-names>Q</given-names></name><name><surname>Guan</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Prostaglandins E2 signal mediated by receptor subtype EP2 promotes IgE production in vivo and contributes to asthma development</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>20505</elocation-id><pub-id pub-id-type="doi">10.1038/srep20505</pub-id><pub-id pub-id-type="pmid">26852804</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halpern</surname> <given-names>AL</given-names></name><name><surname>Kohtz</surname> <given-names>PD</given-names></name><name><surname>Rove</surname> <given-names>JY</given-names></name><name><surname>Ao</surname> <given-names>L</given-names></name><name><surname>Meng</surname> <given-names>X</given-names></name><name><surname>Fullerton</surname> <given-names>DA</given-names></name><name><surname>Weyant</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinoma</article-title><source>Molecular and Cellular Biochemistry</source><volume>456</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1007/s11010-019-03500-3</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heffron</surname> <given-names>SP</given-names></name><name><surname>Weinstock</surname> <given-names>A</given-names></name><name><surname>Scolaro</surname> <given-names>B</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Sansbury</surname> <given-names>BE</given-names></name><name><surname>Marecki</surname> <given-names>G</given-names></name><name><surname>Rolling</surname> <given-names>CC</given-names></name><name><surname>El Bannoudi</surname> <given-names>H</given-names></name><name><surname>Barrett</surname> <given-names>T</given-names></name><name><surname>Canary</surname> <given-names>JW</given-names></name><name><surname>Spite</surname> <given-names>M</given-names></name><name><surname>Berger</surname> <given-names>JS</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Platelet‐conditioned media induces an anti‐inflammatory macrophage phenotype through EP4</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>19</volume><fpage>562</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1111/jth.15172</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hewing</surname> <given-names>B</given-names></name><name><surname>Parathath</surname> <given-names>S</given-names></name><name><surname>Mai</surname> <given-names>CK</given-names></name><name><surname>Fiel</surname> <given-names>MI</given-names></name><name><surname>Guo</surname> <given-names>L</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Rapid regression of atherosclerosis with MTP inhibitor treatment</article-title><source>Atherosclerosis</source><volume>227</volume><fpage>125</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2012.12.026</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillmer</surname> <given-names>EJ</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>HS</given-names></name><name><surname>Watowich</surname> <given-names>SS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>STAT3 signaling in immunity</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>31</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2016.05.001</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jho</surname> <given-names>E</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Domon</surname> <given-names>C</given-names></name><name><surname>Joo</surname> <given-names>C-K</given-names></name><name><surname>Freund</surname> <given-names>J-N</given-names></name><name><surname>Costantini</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Wnt/β-Catenin/Tcf Signaling Induces the Transcription of Axin2, a Negative Regulator of the Signaling Pathway</article-title><source>Molecular and Cellular Biology</source><volume>22</volume><fpage>1172</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1128/MCB.22.4.1172-1183.2002</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jw</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>WS</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name><name><surname>Gan</surname> <given-names>XW</given-names></name><name><surname>Myatt</surname> <given-names>L</given-names></name><name><surname>Sun</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Activation of prostaglandin EP4 receptor attenuates the induction of cyclooxygenase-2 expression by EP2 receptor activation in human amnion fibroblasts: implications for parturition</article-title><source>Faseb J</source><volume>33</volume><fpage>8148</fpage><lpage>8160</lpage></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname> <given-names>VL</given-names></name><name><surname>Szilvassy</surname> <given-names>SJ</given-names></name><name><surname>Daugherty</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Interleukin-4 Deficiency Decreases Atherosclerotic Lesion Formation in a Site-Specific Manner in Female LDL Receptor−/− Mice</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>22</volume><fpage>456</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1161/hq0302.104905</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Handsaker</surname> <given-names>B</given-names></name><name><surname>Wysoker</surname> <given-names>A</given-names></name><name><surname>Fennell</surname> <given-names>T</given-names></name><name><surname>Ruan</surname> <given-names>J</given-names></name><name><surname>Homer</surname> <given-names>N</given-names></name><name><surname>Marth</surname> <given-names>G</given-names></name><name><surname>Abecasis</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Durbin R and genome project data processing S. the sequence alignment/Map format and SAMtools</article-title><source>Bioinformatics</source><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The forgotten majority: unfinished business in cardiovascular risk reduction</article-title><source>Journal of the American College of Cardiology</source><volume>46</volume><fpage>1225</fpage><lpage>1228</lpage></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname> <given-names>P</given-names></name><name><surname>Tabas</surname> <given-names>I</given-names></name><name><surname>Fredman</surname> <given-names>G</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Inflammation and its Resolution as Determinants of Acute Coronary Syndromes</article-title><source>Circulation Research</source><volume>114</volume><fpage>1867</fpage><lpage>1879</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.302699</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieu</surname> <given-names>HD</given-names></name><name><surname>Withycombe</surname> <given-names>SK</given-names></name><name><surname>Walker</surname> <given-names>Q</given-names></name><name><surname>Rong</surname> <given-names>JX</given-names></name><name><surname>Walzem</surname> <given-names>RL</given-names></name><name><surname>Wong</surname> <given-names>JS</given-names></name><name><surname>Hamilton</surname> <given-names>RL</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name><name><surname>Young</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Eliminating Atherogenesis in Mice by Switching Off Hepatic Lipoprotein Secretion</article-title><source>Circulation</source><volume>107</volume><fpage>1315</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000054781.50889.0C</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>J-D</given-names></name><name><surname>Nishi</surname> <given-names>H</given-names></name><name><surname>Poles</surname> <given-names>J</given-names></name><name><surname>Niu</surname> <given-names>X</given-names></name><name><surname>Mccauley</surname> <given-names>C</given-names></name><name><surname>Rahman</surname> <given-names>K</given-names></name><name><surname>Brown</surname> <given-names>EJ</given-names></name><name><surname>Yeung</surname> <given-names>ST</given-names></name><name><surname>Vozhilla</surname> <given-names>N</given-names></name><name><surname>Weinstock</surname> <given-names>A</given-names></name><name><surname>Ramsey</surname> <given-names>SA</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name><name><surname>Loke</surname> <given-names>P’ng</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single-cell analysis of fate-mapped macrophages reveals heterogeneity, including stem-like properties, during atherosclerosis progression and regression</article-title><source>JCI Insight</source><volume>4</volume><elocation-id>e124574</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.124574</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Pan</surname> <given-names>S</given-names></name><name><surname>Hsieh</surname> <given-names>MH</given-names></name><name><surname>Ng</surname> <given-names>N</given-names></name><name><surname>Sun</surname> <given-names>F</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Kasibhatla</surname> <given-names>S</given-names></name><name><surname>Schuller</surname> <given-names>AG</given-names></name><name><surname>Li</surname> <given-names>AG</given-names></name><name><surname>Cheng</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Tompkins</surname> <given-names>C</given-names></name><name><surname>Pferdekamper</surname> <given-names>A</given-names></name><name><surname>Steffy</surname> <given-names>A</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name><name><surname>Kowal</surname> <given-names>C</given-names></name><name><surname>Phung</surname> <given-names>V</given-names></name><name><surname>Guo</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Graham</surname> <given-names>MP</given-names></name><name><surname>Flynn</surname> <given-names>S</given-names></name><name><surname>Brenner</surname> <given-names>JC</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Villarroel</surname> <given-names>MC</given-names></name><name><surname>Schultz</surname> <given-names>PG</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>McNamara</surname> <given-names>P</given-names></name><name><surname>Sellers</surname> <given-names>WR</given-names></name><name><surname>Petruzzelli</surname> <given-names>L</given-names></name><name><surname>Boral</surname> <given-names>AL</given-names></name><name><surname>Seidel</surname> <given-names>HM</given-names></name><name><surname>McLaughlin</surname> <given-names>ME</given-names></name><name><surname>Che</surname> <given-names>J</given-names></name><name><surname>Carey</surname> <given-names>TE</given-names></name><name><surname>Vanasse</surname> <given-names>G</given-names></name><name><surname>Harris</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Targeting Wnt-driven cancer through the inhibition of porcupine by LGK974</article-title><source>PNAS</source><volume>110</volume><fpage>20224</fpage><lpage>20229</lpage><pub-id pub-id-type="doi">10.1073/pnas.1314239110</pub-id><pub-id pub-id-type="pmid">24277854</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Anders</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luan</surname> <given-names>B</given-names></name><name><surname>Yoon</surname> <given-names>YS</given-names></name><name><surname>Le Lay</surname> <given-names>J</given-names></name><name><surname>Kaestner</surname> <given-names>KH</given-names></name><name><surname>Hedrick</surname> <given-names>S</given-names></name><name><surname>Montminy</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CREB pathway links PGE2 signaling with macrophage polarization</article-title><source>PNAS</source><volume>112</volume><fpage>15642</fpage><lpage>15647</lpage><pub-id pub-id-type="doi">10.1073/pnas.1519644112</pub-id><pub-id pub-id-type="pmid">26644581</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lustig</surname> <given-names>B</given-names></name><name><surname>Jerchow</surname> <given-names>B</given-names></name><name><surname>Sachs</surname> <given-names>M</given-names></name><name><surname>Weiler</surname> <given-names>S</given-names></name><name><surname>Pietsch</surname> <given-names>T</given-names></name><name><surname>Karsten</surname> <given-names>U</given-names></name><name><surname>van de Wetering</surname> <given-names>M</given-names></name><name><surname>Clevers</surname> <given-names>H</given-names></name><name><surname>Schlag</surname> <given-names>PM</given-names></name><name><surname>Birchmeier</surname> <given-names>W</given-names></name><name><surname>Behrens</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Negative feedback loop of wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors</article-title><source>Molecular and Cellular Biology</source><volume>22</volume><fpage>1184</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1128/MCB.22.4.1184-1193.2002</pub-id><pub-id pub-id-type="pmid">11809809</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makita</surname> <given-names>N</given-names></name><name><surname>Hizukuri</surname> <given-names>Y</given-names></name><name><surname>Yamashiro</surname> <given-names>K</given-names></name><name><surname>Murakawa</surname> <given-names>M</given-names></name><name><surname>Hayashi</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>IL-10 enhances the phenotype of M2 macrophages induced by IL-4 and confers the ability to increase eosinophil migration</article-title><source>International Immunology</source><volume>27</volume><fpage>131</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxu090</pub-id><pub-id pub-id-type="pmid">25267883</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname> <given-names>A</given-names></name><name><surname>Radhakrishnan</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Mani</surname> <given-names>A</given-names></name><name><surname>Mani</surname> <given-names>MA</given-names></name><name><surname>Nelson-Williams</surname> <given-names>C</given-names></name><name><surname>Carew</surname> <given-names>KS</given-names></name><name><surname>Mane</surname> <given-names>S</given-names></name><name><surname>Najmabadi</surname> <given-names>H</given-names></name><name><surname>Wu</surname> <given-names>D</given-names></name><name><surname>Lifton</surname> <given-names>RP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>LRP6 mutation in a family with early coronary disease and metabolic risk factors</article-title><source>Science</source><volume>315</volume><fpage>1278</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1126/science.1136370</pub-id><pub-id pub-id-type="pmid">17332414</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauer</surname> <given-names>J</given-names></name><name><surname>Chaurasia</surname> <given-names>B</given-names></name><name><surname>Goldau</surname> <given-names>J</given-names></name><name><surname>Vogt</surname> <given-names>MC</given-names></name><name><surname>Ruud</surname> <given-names>J</given-names></name><name><surname>Nguyen</surname> <given-names>KD</given-names></name><name><surname>Theurich</surname> <given-names>S</given-names></name><name><surname>Hausen</surname> <given-names>AC</given-names></name><name><surname>Schmitz</surname> <given-names>J</given-names></name><name><surname>Brönneke</surname> <given-names>HS</given-names></name><name><surname>Estevez</surname> <given-names>E</given-names></name><name><surname>Allen</surname> <given-names>TL</given-names></name><name><surname>Mesaros</surname> <given-names>A</given-names></name><name><surname>Partridge</surname> <given-names>L</given-names></name><name><surname>Febbraio</surname> <given-names>MA</given-names></name><name><surname>Chawla</surname> <given-names>A</given-names></name><name><surname>Wunderlich</surname> <given-names>FT</given-names></name><name><surname>Brüning</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin</article-title><source>Nature Immunology</source><volume>15</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/ni.2865</pub-id><pub-id pub-id-type="pmid">24681566</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minutti</surname> <given-names>CM</given-names></name><name><surname>Jackson-Jones</surname> <given-names>LH</given-names></name><name><surname>García-Fojeda</surname> <given-names>B</given-names></name><name><surname>Knipper</surname> <given-names>JA</given-names></name><name><surname>Sutherland</surname> <given-names>TE</given-names></name><name><surname>Logan</surname> <given-names>N</given-names></name><name><surname>Ringqvist</surname> <given-names>E</given-names></name><name><surname>Guillamat-Prats</surname> <given-names>R</given-names></name><name><surname>Ferenbach</surname> <given-names>DA</given-names></name><name><surname>Artigas</surname> <given-names>A</given-names></name><name><surname>Stamme</surname> <given-names>C</given-names></name><name><surname>Chroneos</surname> <given-names>ZC</given-names></name><name><surname>Zaiss</surname> <given-names>DM</given-names></name><name><surname>Casals</surname> <given-names>C</given-names></name><name><surname>Allen</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Local amplifiers of IL-4Rα-mediated macrophage activation promote repair in lung and liver</article-title><source>Science</source><volume>356</volume><fpage>1076</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1126/science.aaj2067</pub-id><pub-id pub-id-type="pmid">28495878</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munder</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Arginase: an emerging key player in the mammalian immune system</article-title><source>British Journal of Pharmacology</source><volume>158</volume><fpage>638</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00291.x</pub-id><pub-id pub-id-type="pmid">19764983</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunez</surname> <given-names>F</given-names></name><name><surname>Bravo</surname> <given-names>S</given-names></name><name><surname>Cruzat</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Montecino M and de ferrari GV wnt/beta-catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric Cancer cells</article-title><source>PLOS One</source><volume>6</volume><elocation-id>e18562</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0018562</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parathath</surname> <given-names>S</given-names></name><name><surname>Grauer</surname> <given-names>L</given-names></name><name><surname>Huang</surname> <given-names>LS</given-names></name><name><surname>Sanson</surname> <given-names>M</given-names></name><name><surname>Distel</surname> <given-names>E</given-names></name><name><surname>Goldberg</surname> <given-names>IJ</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice</article-title><source>Diabetes</source><volume>60</volume><fpage>1759</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.2337/db10-0778</pub-id><pub-id pub-id-type="pmid">21562077</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peled</surname> <given-names>M</given-names></name><name><surname>Nishi</surname> <given-names>H</given-names></name><name><surname>Weinstock</surname> <given-names>A</given-names></name><name><surname>Barrett</surname> <given-names>TJ</given-names></name><name><surname>Zhou</surname> <given-names>F</given-names></name><name><surname>Quezada</surname> <given-names>A</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A wild-type mouse-based model for the regression of inflammation in atherosclerosis</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0173975</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0173975</pub-id><pub-id pub-id-type="pmid">28291840</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potteaux</surname> <given-names>S</given-names></name><name><surname>Gautier</surname> <given-names>EL</given-names></name><name><surname>Hutchison</surname> <given-names>SB</given-names></name><name><surname>van Rooijen</surname> <given-names>N</given-names></name><name><surname>Rader</surname> <given-names>DJ</given-names></name><name><surname>Thomas</surname> <given-names>MJ</given-names></name><name><surname>Sorci-Thomas</surname> <given-names>MG</given-names></name><name><surname>Randolph</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of apoe–/– mice during disease regression</article-title><source>Journal of Clinical Investigation</source><volume>121</volume><fpage>2025</fpage><lpage>2036</lpage><pub-id pub-id-type="doi">10.1172/JCI43802</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pourcet</surname> <given-names>B</given-names></name><name><surname>Pineda-Torra</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Transcriptional regulation of macrophage arginase 1 expression and its role in atherosclerosis</article-title><source>Trends in Cardiovascular Medicine</source><volume>23</volume><fpage>143</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2012.10.003</pub-id><pub-id pub-id-type="pmid">23375628</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname> <given-names>K</given-names></name><name><surname>Vengrenyuk</surname> <given-names>Y</given-names></name><name><surname>Ramsey</surname> <given-names>SA</given-names></name><name><surname>Vila</surname> <given-names>NR</given-names></name><name><surname>Girgis</surname> <given-names>NM</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Gusarova</surname> <given-names>V</given-names></name><name><surname>Gromada</surname> <given-names>J</given-names></name><name><surname>Weinstock</surname> <given-names>A</given-names></name><name><surname>Moore</surname> <given-names>KJ</given-names></name><name><surname>Loke</surname> <given-names>P’ng</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression</article-title><source>Journal of Clinical Investigation</source><volume>127</volume><fpage>2904</fpage><lpage>2915</lpage><pub-id pub-id-type="doi">10.1172/JCI75005</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname> <given-names>K</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Insights from Pre-Clinical and clinical studies on the role of innate inflammation in atherosclerosis regression</article-title><source>Frontiers in Cardiovascular Medicine</source><volume>5</volume><elocation-id>32</elocation-id><pub-id pub-id-type="doi">10.3389/fcvm.2018.00032</pub-id><pub-id pub-id-type="pmid">29868610</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsey</surname> <given-names>SA</given-names></name><name><surname>Vengrenyuk</surname> <given-names>Y</given-names></name><name><surname>Menon</surname> <given-names>P</given-names></name><name><surname>Podolsky</surname> <given-names>I</given-names></name><name><surname>Feig</surname> <given-names>JE</given-names></name><name><surname>Aderem</surname> <given-names>A</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name><name><surname>Gold</surname> <given-names>ES</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Epigenome-guided analysis of the transcriptome of plaque macrophages during atherosclerosis regression reveals activation of the wnt signaling pathway</article-title><source>PLOS Genetics</source><volume>10</volume><elocation-id>e1004828</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1004828</pub-id><pub-id pub-id-type="pmid">25474352</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roche-Molina</surname> <given-names>M</given-names></name><name><surname>Sanz-Rosa</surname> <given-names>D</given-names></name><name><surname>Cruz</surname> <given-names>FM</given-names></name><name><surname>García-Prieto</surname> <given-names>J</given-names></name><name><surname>López</surname> <given-names>S</given-names></name><name><surname>Abia</surname> <given-names>R</given-names></name><name><surname>Muriana</surname> <given-names>FJ</given-names></name><name><surname>Fuster</surname> <given-names>V</given-names></name><name><surname>Ibáñez</surname> <given-names>B</given-names></name><name><surname>Bernal</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>35</volume><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.114.303617</pub-id><pub-id pub-id-type="pmid">25341796</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname> <given-names>JX</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Reis</surname> <given-names>ED</given-names></name><name><surname>Choudhury</surname> <given-names>RP</given-names></name><name><surname>Dansky</surname> <given-names>HM</given-names></name><name><surname>Elmalem</surname> <given-names>VI</given-names></name><name><surname>Fallon</surname> <given-names>JT</given-names></name><name><surname>Breslow</surname> <given-names>JL</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content</article-title><source>Circulation</source><volume>104</volume><fpage>2447</fpage><lpage>2452</lpage><pub-id pub-id-type="doi">10.1161/hc4501.098952</pub-id><pub-id pub-id-type="pmid">11705823</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutschman</surname> <given-names>R</given-names></name><name><surname>Lang</surname> <given-names>R</given-names></name><name><surname>Hesse</surname> <given-names>M</given-names></name><name><surname>Ihle</surname> <given-names>JN</given-names></name><name><surname>Wynn</surname> <given-names>TA</given-names></name><name><surname>Murray</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Cutting edge: stat6-dependent substrate depletion regulates nitric oxide production</article-title><source>The Journal of Immunology</source><volume>166</volume><fpage>2173</fpage><lpage>2177</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.166.4.2173</pub-id><pub-id pub-id-type="pmid">11160269</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanin</surname> <given-names>DE</given-names></name><name><surname>Matsushita</surname> <given-names>M</given-names></name><name><surname>Klein Geltink</surname> <given-names>RI</given-names></name><name><surname>Grzes</surname> <given-names>KM</given-names></name><name><surname>van Teijlingen Bakker</surname> <given-names>N</given-names></name><name><surname>Corrado</surname> <given-names>M</given-names></name><name><surname>Kabat</surname> <given-names>AM</given-names></name><name><surname>Buck</surname> <given-names>MD</given-names></name><name><surname>Qiu</surname> <given-names>J</given-names></name><name><surname>Lawless</surname> <given-names>SJ</given-names></name><name><surname>Cameron</surname> <given-names>AM</given-names></name><name><surname>Villa</surname> <given-names>M</given-names></name><name><surname>Baixauli</surname> <given-names>F</given-names></name><name><surname>Patterson</surname> <given-names>AE</given-names></name><name><surname>Hässler</surname> <given-names>F</given-names></name><name><surname>Curtis</surname> <given-names>JD</given-names></name><name><surname>O'Neill</surname> <given-names>CM</given-names></name><name><surname>O'Sullivan</surname> <given-names>D</given-names></name><name><surname>Wu</surname> <given-names>D</given-names></name><name><surname>Mittler</surname> <given-names>G</given-names></name><name><surname>Huang</surname> <given-names>SC</given-names></name><name><surname>Pearce</surname> <given-names>EL</given-names></name><name><surname>Pearce</surname> <given-names>EJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mitochondrial membrane potential regulates nuclear gene expression in macrophages exposed to prostaglandin E2</article-title><source>Immunity</source><volume>49</volume><fpage>1021</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.10.011</pub-id><pub-id pub-id-type="pmid">30566880</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname> <given-names>CA</given-names></name><name><surname>Rasband</surname> <given-names>WS</given-names></name><name><surname>Eliceiri</surname> <given-names>KW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>NIH image to ImageJ: 25 years of image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2089</pub-id><pub-id pub-id-type="pmid">22930834</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname> <given-names>M</given-names></name><name><surname>Schlegel</surname> <given-names>MP</given-names></name><name><surname>Afonso</surname> <given-names>MS</given-names></name><name><surname>Brown</surname> <given-names>EJ</given-names></name><name><surname>Rahman</surname> <given-names>K</given-names></name><name><surname>Weinstock</surname> <given-names>A</given-names></name><name><surname>Sansbury</surname> <given-names>BE</given-names></name><name><surname>Corr</surname> <given-names>EM</given-names></name><name><surname>van Solingen</surname> <given-names>C</given-names></name><name><surname>Koelwyn</surname> <given-names>GJ</given-names></name><name><surname>Shanley</surname> <given-names>LC</given-names></name><name><surname>Beckett</surname> <given-names>L</given-names></name><name><surname>Peled</surname> <given-names>D</given-names></name><name><surname>Lafaille</surname> <given-names>JJ</given-names></name><name><surname>Spite</surname> <given-names>M</given-names></name><name><surname>Loke</surname> <given-names>P</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name><name><surname>Moore</surname> <given-names>KJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Regulatory T cells license macrophage Pro-Resolving functions during atherosclerosis regression</article-title><source>Circulation Research</source><volume>127</volume><fpage>335</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.316461</pub-id><pub-id pub-id-type="pmid">32336197</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>EH</given-names></name><name><surname>Shimizu</surname> <given-names>K</given-names></name><name><surname>Christen</surname> <given-names>T</given-names></name><name><surname>Rocha</surname> <given-names>VZ</given-names></name><name><surname>Shvartz</surname> <given-names>E</given-names></name><name><surname>Tesmenitsky</surname> <given-names>Y</given-names></name><name><surname>Sukhova</surname> <given-names>G</given-names></name><name><surname>Shi</surname> <given-names>GP</given-names></name><name><surname>Libby</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Lack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesions</article-title><source>Cardiovascular Research</source><volume>89</volume><fpage>234</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvq262</pub-id><pub-id pub-id-type="pmid">20736236</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>J</given-names></name><name><surname>Lobatto</surname> <given-names>ME</given-names></name><name><surname>Hassing</surname> <given-names>L</given-names></name><name><surname>van der Staay</surname> <given-names>S</given-names></name><name><surname>van Rijs</surname> <given-names>SM</given-names></name><name><surname>Calcagno</surname> <given-names>C</given-names></name><name><surname>Braza</surname> <given-names>MS</given-names></name><name><surname>Baxter</surname> <given-names>S</given-names></name><name><surname>Fay</surname> <given-names>F</given-names></name><name><surname>Sanchez-Gaytan</surname> <given-names>BL</given-names></name><name><surname>Duivenvoorden</surname> <given-names>R</given-names></name><name><surname>Sager</surname> <given-names>H</given-names></name><name><surname>Astudillo</surname> <given-names>YM</given-names></name><name><surname>Leong</surname> <given-names>W</given-names></name><name><surname>Ramachandran</surname> <given-names>S</given-names></name><name><surname>Storm</surname> <given-names>G</given-names></name><name><surname>Pérez-Medina</surname> <given-names>C</given-names></name><name><surname>Reiner</surname> <given-names>T</given-names></name><name><surname>Cormode</surname> <given-names>DP</given-names></name><name><surname>Strijkers</surname> <given-names>GJ</given-names></name><name><surname>Stroes</surname> <given-names>ES</given-names></name><name><surname>Swirski</surname> <given-names>FK</given-names></name><name><surname>Nahrendorf</surname> <given-names>M</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name><name><surname>Fayad</surname> <given-names>ZA</given-names></name><name><surname>Mulder</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation</article-title><source>Science Advances</source><volume>1</volume><elocation-id>e1400223</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.1400223</pub-id><pub-id pub-id-type="pmid">26295063</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trogan</surname> <given-names>E</given-names></name><name><surname>Choudhury</surname> <given-names>RP</given-names></name><name><surname>Dansky</surname> <given-names>HM</given-names></name><name><surname>Rong</surname> <given-names>JX</given-names></name><name><surname>Breslow</surname> <given-names>JL</given-names></name><name><surname>Fisher</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice</article-title><source>PNAS</source><volume>99</volume><fpage>2234</fpage><lpage>2239</lpage><pub-id pub-id-type="doi">10.1073/pnas.042683999</pub-id><pub-id pub-id-type="pmid">11842210</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallerie</surname> <given-names>SN</given-names></name><name><surname>Kramer</surname> <given-names>F</given-names></name><name><surname>Barnhart</surname> <given-names>S</given-names></name><name><surname>Kanter</surname> <given-names>JE</given-names></name><name><surname>Breyer</surname> <given-names>RM</given-names></name><name><surname>Andreasson</surname> <given-names>KI</given-names></name><name><surname>Bornfeldt</surname> <given-names>KE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Myeloid cell prostaglandin E2 receptor EP4 modulates cytokine production but not atherogenesis in a mouse model of type 1 diabetes</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0158316</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0158316</pub-id><pub-id pub-id-type="pmid">27351842</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Dyken</surname> <given-names>SJ</given-names></name><name><surname>Locksley</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease</article-title><source>Annual Review of Immunology</source><volume>31</volume><fpage>317</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095906</pub-id><pub-id pub-id-type="pmid">23298208</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Guo</surname> <given-names>C</given-names></name><name><surname>Zhu</surname> <given-names>P</given-names></name><name><surname>Lu</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Xie</surname> <given-names>H</given-names></name><name><surname>Myatt</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Sun</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Phosphorylation of STAT3 mediates the induction of cyclooxygenase-2 by cortisol in the human amnion at parturition</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>ra106</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aac6151</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>F</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Park</surname> <given-names>S-H</given-names></name><name><surname>Gwag</surname> <given-names>T</given-names></name><name><surname>Lu</surname> <given-names>W</given-names></name><name><surname>Ma</surname> <given-names>M</given-names></name><name><surname>Sui</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Myeloid β-Catenin Deficiency Exacerbates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>38</volume><fpage>1468</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.118.311059</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="software"><person-group person-group-type="author"><collab>WHO</collab></person-group><year iso-8601-date="2017">2017</year><source>Cardiovascular Diseases (CVDs)</source></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Murphy</surname> <given-names>SL</given-names></name><name><surname>Kochanek</surname> <given-names>KD</given-names></name><name><surname>Arias</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mortality in the united states, 2015</article-title><source>NCHS Data Brief</source><volume>267</volume><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>HW</given-names></name><name><surname>Bowman</surname> <given-names>RL</given-names></name><name><surname>Joyce</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>STAT3 and STAT6 signaling pathways synergize to promote cathepsin secretion from macrophages via IRE1α activation</article-title><source>Cell Reports</source><volume>16</volume><fpage>2914</fpage><lpage>2927</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.08.035</pub-id><pub-id pub-id-type="pmid">27626662</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yurdagul</surname> <given-names>A</given-names></name><name><surname>Subramanian</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Crown</surname> <given-names>SB</given-names></name><name><surname>Ilkayeva</surname> <given-names>OR</given-names></name><name><surname>Darville</surname> <given-names>L</given-names></name><name><surname>Kolluru</surname> <given-names>GK</given-names></name><name><surname>Rymond</surname> <given-names>CC</given-names></name><name><surname>Gerlach</surname> <given-names>BD</given-names></name><name><surname>Zheng</surname> <given-names>Z</given-names></name><name><surname>Kuriakose</surname> <given-names>G</given-names></name><name><surname>Kevil</surname> <given-names>CG</given-names></name><name><surname>Koomen</surname> <given-names>JM</given-names></name><name><surname>Cleveland</surname> <given-names>JL</given-names></name><name><surname>Muoio</surname> <given-names>DM</given-names></name><name><surname>Tabas</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Macrophage metabolism of apoptotic Cell-Derived arginine promotes continual efferocytosis and resolution of injury</article-title><source>Cell Metabolism</source><volume>31</volume><fpage>518</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.01.001</pub-id><pub-id pub-id-type="pmid">32004476</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67932.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing Editor</role><aff><institution>James J. Peters Veterans Affairs Medical Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>[Editors' note: this paper was reviewed by <ext-link ext-link-type="uri" xlink:href="https://www.reviewcommons.org/">Review Commons</ext-link>.]</p><p><bold>Acceptance summary:</bold></p><p>This paper sought to investigate the roles of two interleukins, IL-4 and IL-13, in atherosclerosis aka hardened arteries. The authors note that global IL-4 and IL-13 deficiency impairs atherosclerosis resolution, but unexpectedly that the interleukin levels do not change during resolution of atherosclerosis. This led them to a discover a model whereby wnt3a signaling induces prostaglandin (PGE2) production and STAT3 activation. The combination of reduced lipid intake activating wnt3a/PGE2/STAT3 combined with STAT6 activation downstream of IL-4 signaling, led to a transcriptional synergy serving to promote atherosclerosis resolution. Overall, this manuscript helps define a combined pathway whereby inflammation and lipids together interact to help determine the fate of atherosclerosis.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67932.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>We first want to thank the reviewers for their enthusiasm and support, as well as for insightful and comprehensive comments that we addressed to improve our manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer 1:</p><p>Figure 1. I am missing the control experiment using Il4/13-proficient mice. To make the claim that IL4/13 are needed for significant atherosclerosis resolution that control (although in general published already) would be good to have in the same experimental set-up. Or is everything really identical to the Sharma et al. study (BL6 mice, PCSK9-AAV construct and administration conditions)? If so, this should be clearly stated and perhaps the experimental details re-iterated in Materials and methods.</p></disp-quote><p>The study design and mouse model are indeed identical to Sharma et al. We have extended the Materials and methods section to explain the model more thoroughly.</p><disp-quote content-type="editor-comment"><p>Figure 3. The cytokine analysis experiment in Figure 3A is not fully convincing. Chemokines such as MCP-1 (which BTW should be termed CCL2 to abide by current nomenclature) are well known to be endothelially deposited due to their high GAG binding property and to be prestored in vesicles. Can authors comment on how IL4 and IL-13 behave in this context? Can washout effects be excluded? Furthermore, could the almost undetectable levels of IL-13 be due to a washout effect? Along the same line: were the ELISA data confirmed by qPCR? If IL-13 levels were &quot;underestimated&quot;, it may not have been fully justified to subsequently only focus on IL-4?</p></disp-quote><p>The name of the chemokine was altered in the figure and text to CCL2. Due to the experimental procedure, we do not believe that there was a washout of IL-13: plaques were excised and placed in a tube containing PBS and proteinase inhibitor. Plaques were then physically disrupted with a homogenizer and suspensions were measured directly, without any washing steps. In the same assay we also measured additional cytokines, which are not the focus of this manuscript, but are added in <xref ref-type="fig" rid="respfig1">Author response image 1</xref> for reviewer’s appreciation.</p><fig id="respfig1"><label>Author response image 1.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-resp-fig1-v3.tif"/></fig><p>Additionally and in accordance with the reviewer’s suggestion, we examined the expression IL-13 in our previously published scRNAseq datasets of atherosclerosis resolution, and added these to Figure 3—figure supplement 1. The data demonstrate that IL-13 was only expressed in 1 cell in the entire dataset, further validating our observation of undetectable IL-13 levels.Furthermore, although less relevant in the context of plaque resolution, we believe our findings of enhancement of the Th2 cytokine response by Wnt extends to IL-13 as well. We examined the expression of related genes in macrophages treated with Wnt3a and IL-13 and observed a very similar increase in the expression to the response observed with IL-4 + Wnt3a treatment (n=9):</p><fig id="respfig2"><label>Author response image 2.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-resp-fig2-v3.tif"/></fig><disp-quote content-type="editor-comment"><p>Figure 4. The human correlation data for Axin2 in Figure 4F is very intriguing and convincing, but also raises the questions whether other Wnt signature genes such a β-catenin showed a similar correlation?</p></disp-quote><p>As per the reviewer’s suggestion, we examined the association of plaque volume change with the expression of β catenin in the human study. Results show no association between the two parameters. With that said, β-catenin is mostly regulated at the protein level upon Wnt activation, whereas Axin2 is mostly transcriptionally regulated (via β-catenin protein transcriptional activation; Dzobo K et al. Journal of Integrative Biology, 2019), which likely accounts for these differences.</p><fig id="respfig3"><label>Author response image 3.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67932-resp-fig3-v3.tif"/></fig><disp-quote content-type="editor-comment"><p>Figure 5. While the data show that the combination of Wnt3a and IL4 enhances the expression of Arg1, Ccl17, and Socs1, authors should refine the use of the term &quot;synergistic&quot;. Synergism is actually only observed if one considers the addition of IL-4 to the Wnt3a-treated incubation. If one compares the IL-4 effect with that of the IL-4 + Wnt3a combination, the effect sees is &quot;only&quot; &quot;additive&quot;.</p></disp-quote><p>We agree with the reviewer and refined these statements throughout the manuscript.</p><disp-quote content-type="editor-comment"><p>Also, the synergistic effect of IL-4 regarding activation by Wnt3a should also be shown on the level of (rapid) signal transduction, e.g. by looking at rapid signaling effects downstream of Wnt3a/FRZ/LRP (phosphorylation, protein level).</p></disp-quote><p>The molecular mechanism demonstrated in the manuscript is the activation of STAT3 (i.e., its phosphorylation), via the production of PGE2 by Wnt-stimulated macrophages. To investigate the rapidity of this signal transduction, we treated primary macrophages with Wnt3a or its conditioned media for 15, 30 and 60 minutes, which did not cause STAT3 phosphorylation by the indicated time points. Conditioned media from cells incubated with Wnt3a for 16 hours, however, did promote STAT3 phosphorylation within this short time frame as early as 15 minutes (Figure 7—figure supplement 1E). We are happy move these data to the main figures, if the reviewer thinks it will be more appropriate there.</p><disp-quote content-type="editor-comment"><p>Figure 7. Based on the data in Figure 7, authors insinuate the IL-6/STAT3 axis to synergize with IL-4 in skewing plaque macrophages towards a reparative/resolution phenotype. How do they reconcile the suggested role of IL-6 as a downstream target of IL-1b in promoting atherosclerotic inflammation (CANTOS)?</p></disp-quote><p>The reviewer brings up an interesting point, and the dichotomy of STAT3 as a factor either anti (in response to IL-10) or pro-inflammatory (in response to IL-6) is of interest to many. The experiment described in this manuscript, in which both IL-10 and IL-6 enhanced the response to IL-4 was a demonstration of the cooperation between STAT6 and STAT3 when both are activated. Our interpretation of the data is that the STAT3 activator in response to Wnt is PGE<sub>2</sub>, and not IL-6, as supported by the experiments in which PGE<sub>2</sub> receptor binding was blocked (add any other PGE<sub>2</sub>-based strategy we used). It is likely that factors upstream or downstream of STAT3 may affect the selection of its transcriptional targets.</p><disp-quote content-type="editor-comment"><p>Figure 8. In the cartoon in Figure 8, authors imply a &quot;paracrine&quot; mechanism of Wnt3a-driven PGE2 production and PGE2-mediated STAT3 activation. Could this also happen in an &quot;autocrine&quot; manner? Please consider and discuss!</p></disp-quote><p>The reviewer is absolutely right, as we do not know if the effects are paracrine, autocrine or both. We, thus, revised our cartoon and added this point to the Discussion.</p><disp-quote content-type="editor-comment"><p>The Introduction is a bit &quot;thin&quot; and could be expanded.</p></disp-quote><p>The Introduction was expanded.</p><disp-quote content-type="editor-comment"><p>Cytokine names IL-4 and IL-13 should be written with &quot;hyphen&quot;, i.e. &quot;IL-4&quot; not &quot;IL4&quot; as usually spelled in the field.</p></disp-quote><p>The names were revised to include a hyphen.</p><disp-quote content-type="editor-comment"><p>I would fully label the Il4/Il13-DKO as &quot;Il4<sup>-/-</sup> Il13<sup>-/-</sup>&quot;. The chosen abbreviation &quot;Il4/Il13<sup>-/-</sup>&quot; could create confusion as it doesn't clearly indicate that the Il4 gene is knocked out as well.</p></disp-quote><p>The abbreviation was revised, as suggested.</p><disp-quote content-type="editor-comment"><p>This sentence in results is confusing and seems disconnected: &quot;Prior to transplant/lipid reduction, cells in the plaques are sufficient for IL4/13, while cells recruited post-transplant are deficient.&quot; Does it refer to an actual experiment? If so, were IL-4 and IL-13 measured?</p></disp-quote><p>This sentence was part of the explanation for the experiment. We removed the sentence.</p><disp-quote content-type="editor-comment"><p>Results section, it should read &quot;Wnt3a protein and IL4&quot; instead of “Wnt3a protein with IL4&quot;.</p></disp-quote><p>This was revised, as suggested.</p><disp-quote content-type="editor-comment"><p>Reviewer 2:</p><p>I respectfully point out that Figure 1 is missing the WT controls so it is difficult to interpret the data. In general, I agree with the authors that the DKO are resistant to the regression model but whether that is because their plaques are very small or don't shrink cannot be formally deduced from the experimental layout. So, both wording and conclusions should be chosen more carefully.</p></disp-quote><p>Please find response to reviewer 1 (answer 1) in regards to the mouse model. We agree with the reviewer that detecting shrinkage of very small plaques would be a challenge. However, the plaques analyzed in Figure 1 are of average size of 319,293µm<sup>2</sup> and we have previously demonstrated effective atherosclerosis resolution in plaques smaller than 200,000µm<sup>2</sup> (Sharma et al., 2020 and Basu et al., 2018). Moreover, it is possible that the IL-4/13 DKO mice have smaller plaques than WT mice after Western Diet feeding, but given that plaque size is substantial, we think that the conclusion that these cytokines are needed for disease resolution holds. As suggested by the reviewer, we added a Discussion section for this potential caveat and thank both reviewers for raising this issue.</p><disp-quote content-type="editor-comment"><p>In the end, it remains unclear to me what the authors propose which cells signal the Wnt pathway where and when during atherogenesis and regression. I think the authors need a better model to grasp their hypotheses.</p></disp-quote><p>The focus of this manuscript is the cells <italic>responding</italic> to Wnt (macrophages), which become pro-reparative in response. We agree with the reviewer that the cells which produce Wnt and the exact time of response to Wnt is still unknown and is beyond the scope of this manuscript. Indeed, these questions are an active area of investigation in our group.</p><disp-quote content-type="editor-comment"><p>What is the plasma count of monocytes (more detailed by FACS, not just total leukocyte count) in the experiments? Do the altered numbers in the plaque reflect altered invasion or overall altered numbers, e.g. in the Wnt inhibitor experiment.</p></disp-quote><p>We added flow-cytometry data of Ly6c hi and Ly6c low monocytes to Figure 6—figure supplement 1F. The data show similar frequencies of these cells in the circulation, such that increased proportions of these cells is probably not the reason for the impaired resolution upon Wnt inhibition.</p><disp-quote content-type="editor-comment"><p>Some of the stats are stated correctly but I find it hard to believe that these numbers provide significance based on the data points. I would actually redo the math if I was reviewing the final version (see Figure 7F).</p></disp-quote><p>Thank you for the meticulous examination of the data. We repeated the analysis and received the same values as presented in the figure. In author response table 1 are the raw expression values for your additional review:</p><table-wrap id="resptable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th/><th/><th>Control siRNA</th><th/><th/><th>STAT3 siRNA</th><th/><th/><th/></tr></thead><tbody><tr><td>Biological replicate</td><td>Untreated</td><td>Wnt3a</td><td>IL4</td><td>Wnt+IL4</td><td>Untreated</td><td>Wnt3a</td><td>IL4</td><td>Wnt+IL4</td></tr><tr><td>1</td><td>0.000107</td><td>0.00025</td><td>0.017898</td><td>0.065526</td><td>0.000236</td><td>0.00018</td><td>0.00649</td><td>0.015214</td></tr><tr><td>2</td><td>7.54E-05</td><td>0.000137</td><td>0.004711</td><td>0.020549</td><td>4.2E-05</td><td>1.21E-05</td><td>0.001987</td><td>0.009788</td></tr><tr><td>3</td><td>0.000107</td><td>0.00025</td><td>0.017898</td><td>0.065526</td><td>0.000236</td><td>0.00018</td><td>0.00649</td><td>0.015214</td></tr><tr><td>4</td><td>0.000373</td><td>0.000343</td><td>0.000846</td><td>0.01827</td><td>0.000193</td><td>0.000239</td><td>0.000954</td><td>0.004027</td></tr><tr><td>5</td><td>9.18E-05</td><td>0</td><td>0.003173</td><td>0.009634</td><td>6.84E-05</td><td>0.000105</td><td>0.001183</td><td>0.001899</td></tr></tbody></table></table-wrap><p>Performing 1-way ANOVA only of the STAT3 siRNA conditions still did not yield statistical significance, whereas a t-test of IL-4 versus Wnt+IL-4 resulted in a significant p-value of 0.02. With that said, we believe that a 2-way ANOVA is the most appropriate test for these data.</p><disp-quote content-type="editor-comment"><p>Green/red, red/blue on black for IMF/IHC (Figure 6F, 7G, is not ideal, I would use black/white color scale – enhances contrast for the readers and is inclusive.</p></disp-quote><p>Images were revised, as suggested by the reviewer.</p><disp-quote content-type="editor-comment"><p>The scheme depicting the experimental approach in the figures (1A, 2A, 3B, 6A etc.) can be more detailed.</p></disp-quote><p>We agree with the reviewer and added more details to the experimental approach figures.</p><disp-quote content-type="editor-comment"><p>The Introduction is very short compared to the rest. I would like to read more about what is known already in more detail.</p></disp-quote><p>The Introduction was expanded.</p></body></sub-article></article>